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ABSTRACT 
 
Promiscuous compounds, specifically aggregate-based inhibitors that result in false positives in 
biochemical activity assays present a serious and increasing interference to early-stage drug 
discovery processes. Although under-used, a number of purpose-specific assays have been 
developed to enable the identification of promiscuous inhibitors. To advance on these efforts, this 
study aimed to develop and optimise a novel thermal shift assay to concurrently identify both true 
and promiscuous inhibitors. In particular, stem bromelain selected as the model protein for this 
study was successfully isolated from the bromelain mixture through molecular exclusion 
chromatography and shown to be enzymatically active in the titrimetric assay (gelatin digestive 
unit/gm enzyme of 2024.36-2085.5). The radial diffusion assay predicted that the promiscuous 
compound Epigallocatechin gallate and the known aggregate based-promiscuous compound 
Congo Red activated the digestion of gelatin by stem bromelain. In the thermal shift assay, 
bromelain yielded a melting temperature of ~75-76 °C which then shifted by 9 °C in the presence 
of a true inhibitor E-64. A similar shift was surprisingly observed in the presence of 
Epigallocatechin gallate and both these compounds were similarly not affected by the presence 
of a detergent (0.004% sodium dodecyl sulfate). The protein was aggregated in the presence of 
Congo Red, however, the addition of the detergent effectively restored the protein to its original 
melting temperature. Both Epigallocatechin gallate and Congo Red demonstrated cytotoxicity. As 
a proof of concept, this study showed that in addition to identifying true inhibitors, the detergent-
based thermal shift assay can be successfully employed to identify promiscuous inhibitors and to 
determine different mechanisms. 
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Chapter 1: Introduction 
 
1.1. Drug discovery and development 
The process of drug discovery and development is complex, it involves several steps and as 
such, it takes years before a drug reaches the market (Figure 1.1). Additionally, the process 
of producing a successful drug can range from $1.3 billion to $12 billion of costs as stated in 
Herper, 2012. Early-stage drug discovery is the initial phase of the discovery and development 
pipeline (Figure 1.1). This phase is initiated in search of suitable medical products to treat 
clinical conditions and diseases whose clinical needs are not met, as reviewed in Hughes et 
al., 2011.  
 
Figure 1.1: The drug discovery development and pipeline. The process of drug development 
highlighting different stages of the pipeline and the estimated duration of each stage. Drug discovery is 
the initial stage of this process with several assays used to generate leads, followed by the pre-clinical 
where lead compounds undergo further validation both in vitro and in vivo. Once validated, the next 
stage is the clinical trial which is divided into three phases. The success of these stages promote the 
approval stage that comes before the drug is available in the market. Figure obtained from Matthews 
et al., 2016.
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Like any other scientific process, drug discovery starts with intensive research about a 
potential drug candidate before developing a theory that promoting, blocking or modifying the 
interactions of a pathway, or protein or a target may lead to a therapeutic benefit for a clinical 
condition or disease (Hughes et al., 2011). Driven by this theory, the proceeding steps usually 
involve the selection of a potential target that is further validated before progressing into the 
lead discovery phase. Once at this phase, approximately 5 000 - 10 000 compounds undergo 
thorough tests in the quest for one potential marketed drug. Out of the compounds tested, 
approximately 250 compounds proceed into preclinical development as leads for further 
validation (Figure 1.1) (Hughes et al., 2011). If a lead proves to be effective, it progresses to 
clinical development and eventually into a marketed drug (Alvarez and Shoichet, 2005). 
1.2. Different approaches to lead identification  
Drug discovery uses several approaches to acquire novel drug compounds, these include 
non-random screening and clinical observation. The random and rational drug design 
approaches, both extensively used when seeking new compounds are discussed below.   
1.2.1. Rational drug design   
Unlike the traditional try-and-error methods used in drug discovery, the rational approach uses 
a collection of computational methods whose success is not subject to chance alone, but 
mostly dependent on the initial knowledge of the effect that a compound will have on a specific 
target (Parrill and Reddy, 1999; Baldi, 2010; Kalyani et al., 2013). Briefly, this approach 
involves designing small molecules called HITS with desired or even predefined properties for 
a target whose function may be known or unknown (Mandal et al., 2009). These HITS are 
compounds that bring about desired effect on a specific target, they are identified by screening 
libraries of compounds against specific proteins for further development into potential leads 
(Wunberg et al., 2006). Ligand-based and structure-based drug design sum up the facets of 
rational drug design as shown in Figure 1.2. The key difference is that structure-based drug 
design exploits information of a known or predicted target structure (Bohacek et al., 1996). 
Whereas in ligand-based drug design information about the compound (ligand) that binds to 
the target is exploited (Marrone et al., 1997; Kurogi and Guner, 2001; Aparoy et al., 2012). 
The ligand-based design is often used in the absence of a three-dimensional (3D) structure of 
the target. Using several tools such as the 3D quantitative structure-activity relationship 
(QSAR), ligand-based drug design has led to the identification of pharmaceutical products that 
have contributed to drug discovery. Examples include the acetylcholinesterase inhibitor 
donepezil hydrochloride used in patients with Alzheimer’s disease under the market name 
Aricept (Kawakami et al., 1996). 
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1.2.2. Random drug discovery 
This approach which is highly dependent on chance revolves around the random screening of 
thousands of molecules in hope of finding compounds that have activating or inhibiting 
properties towards a target. The screened compounds which are often sourced from synthetic 
chemicals, marine or microbial origin and natural plant products undergo a series of tests 
before a compound can be optimized as a lead (Boehm et al., 2000; Kalyani et al., 2013).  
Even though it went through a period of being overlooked in the past, random drug design has 
improved over the years through the development of new technologies (Figure 1.2), some of 
which are discussed below. 
 
  
   
 
 
 
  
 
 
 
 
 
 
Figure 1.2: An overview of random and rational approach in drug discovery. The lead identification 
approaches; random and rational drug design showing different techniques applied for each approach. 
These all promote lead optimization and pre-clinical development. The modified image was adapted 
from Hewer et al., 2012.
Random drug-design 
 
 High-throughput screening 
 Natural product screening 
 Fragment-based screening 
 Combinatorial chemistry 
 
 
 
 
 
 
Rational drug design 
 
Structure-based drug design 
 X-Ray crystallography  
 NMR Spectroscopy 
 Homology modelling  
 Computer aided design 
 Structure genomics 
 Fragment-based design  
Ligand-based drug design  
 Computer aided design 
 2D/3D structure matching 
 QSAR                      
  
Lead 
optimization  
Pre-clinical Development  
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1.2.2.1. Combinatorial chemistry  
Combinatorial chemistry encompasses the chemical synthesis that enables the generation of 
a large array of chemically diverse compounds commonly referred to as a library (Darvas et 
al., 2001). This is achieved through a systematic linkage of chemical building blocks to explore 
all possible combinations (Figure 1.3). The solid phase is employed during compound 
synthesis where chemicals are put on resin beads which can be easily washed off or removed 
once the linkage or reaction is complete (Ohlmeyer et al., 1993).  
 
 
 
 
   
 
 
 
 
 
 
 
Figure 1.3: A typical combinatorial chemistry process. An illustration of how compounds are 
synthesized using combinatory chemistry, the red circles represent the beads that link each chemical. 
The chemicals are then mixed and divided into three containers (1), where all the containers have 
identical sets (2). The chemicals shown in 1 are then added to the three containers to obtain all possible 
combinations (3). 
This highly automated technique used for lead identification has elevated random drug 
discovery as it produces large libraries of compounds in a shortened time (Miertus et al., 
2000). Following the testing of these lead compounds against potential drug targets is a lead 
optimization technique with similar properties as combinatorial chemistry. This technique is 
called parallel synthesis, and it uses more focused methods to further produce a great number 
of variants of the potential leads. Another dominantly used technology in drug discovery is
2. Mix and divide 
3. Add the three individual chemicals to each 
container  
1. Three different 
chemicals linked 
to beads  
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called the high-throughput screening (HTS) (Jadhav et al., 2009; Chan et al., 2009). 
Combinatorial chemistry runs parallel with HTS; where combinatorial chemistry made possible 
the generation of huge numbers of new compounds to feed into the screening machines, and 
HTS could run through the new combinatorial compound libraries at a fast rate (Miertus et al., 
2000; Darvas et al., 2001; Jadhav et al., 2009).   
1.2.2.2. High throughput screening  
HTS is a process whereby hundreds of thousands of samples are assayed and screened 
against specific targets under given conditions (Szymański et al., 2011). This process is 
guided by four elements, the first one being suitably arranged compound libraries which are 
normally obtained from combinatorial synthesis or products extracted from natural plants 
(Broach and Thorner, 1996). The samples or libraries used can be of different biochemical 
nature such as live cells, protein, chemical compounds or peptides (del Álamo et al., 2016). 
The second element involves the development of a screening assay, where assay conditions 
are validated to screen the arrayed compound library (Broach and Thorner, 1996). Thirdly, it 
requires a robotic workstation for which assays are usually automated in the form of 96-well 
plates. The final element is the analysis which requires a computerized system to handle and 
analyze data (Broach and Thorner, 1996). Currently, with the help of the robotic equipment 
that systematizes this process, more than 100,000 samples can be screened and analyzed a 
day. It is through this advantage that HTS is popular in science since it enables the generation 
of a reliable database of lead compounds in a short amount of time (Janzen, 2014). However, 
the actual preparation steps involved in HTS; sample preparation, sample handling, and data 
analysis can take days (Dragiev et al., 2011).  
Over the years, HTS has become a cohesive part of drug discovery processes. This is 
because the method enables the rapid identification of HITS or small molecules that can 
further be generated into leads that specifically inhibit enzyme function (Feng et al., 2005; 
Wunberg et al., 2006). The main goal of HTS is to identify HITS that are active at low a 
concentration. The lower the concentration at which the compound is found to be effective, 
the more likely that it will exhibit specificity, and as a result, the less likely that it will have 
undesired side effects (Broach and Thorner, 1996).
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1.3. Promiscuous compounds as a challenge facing drug discovery  
Promiscuous compounds are defined as non-specific small molecules that can interact (inhibit 
or activate) with more than one target (Ingólfsson et al., 2014). These targets can vary in 
structure, function and even originate from different families. In their pursuit to understand 
these compounds, Hu and Bajorath described compound promiscuity under assay conditions 
as the presence of specific interactions amongst micro molecules and a variety of biological 
targets (Hu and Bajorath, 2013). According to this definition, promiscuous compounds not only 
interact with targets, but they can also interact with each other, hence they are called 
promiscuous due to their unselective nature. The unintentional identification of promiscuous 
compounds wastes time and resources which can be dedicated to pursuing compounds that 
can be further developed into potential drugs (Roche et al., 2002). A number of compounds 
(toxoflavin, rhodanines etc.) have been exposed to have promiscuous activity, however, 
regardless of this knowledge, such compounds are still being used as potential leads (Bruns 
and Watson, 2012). 
1.3.1. Typical behaviors of promiscuous compounds  
Promiscuous compounds are usually identified by their puzzling behaviors in biochemical 
assays. These include a steep-dose response curve, concentration-dependent inhibition, 
flattened structure-activity relationship, and inhibition of unrelated targets. In 2012, Bruns and 
Watson developed a set of 275 rules that guide the identification of compounds that interfere 
with biological assays so that they can be eliminated in screening sets (Bruns and Watson, 
2012). Mostly, these rules are based on the structure (for example, ring, halogen, aldehyde 
etc) and function (protecting groups, chelators etc.) of the compounds (Bruns and Watson, 
2012).  
The dose-response curve explains the relationship between the activity of a compound (the 
effect) and its concentration (the given amount), (Walters and Namchuk, 2003). One common 
indication of promiscuity among HITS is a high Hill slope shown in a steep dose-response 
curve. Hence, compounds with a slope of much greater than one should not be regarded as 
HITS in biochemical assays.  For promiscuous compounds, inhibition increases with an 
increase in concentration which is expected. A comparison of the acceptable Hill slope and 
the rejected one is shown in Figure 1.4, ‘compound a’ has a Hill slope of 1.3 which makes the 
compound acceptable whereas ‘compound b’ has a higher Hill slope of 8.6 which makes it 
unacceptable.
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Figure 1.4: Dose-response curves comparing two different compounds with the same IC50. Image 
adopted from Walters and Namchuk, 2003. 
1.3.2. Mechanism of action   
Although promiscuous compounds have received a lot of research attention over the years, 
still not much is certain about their mechanism of inhibition or stoichiometry towards the target. 
One of the common mechanisms amongst promiscuous compounds are the aggregate 
inducing compounds which results in false positives. Table 1.1 shows examples of other 
promiscuous compounds known as Pan Assay Interference Compounds (PAINS) which have 
been identified in high throughput screens. These compounds were identified by their ability 
to act as promising, but misleading HITS against different and unrelated targets (Dahlin et al., 
2015; Dahlin and Walters, 2016). As shown in Table 1.1, these compounds can interact with 
the target using three mechanisms of action, namely; redox recycling, metal complexation, 
and covalent modification.
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Table 1.1: Different mechanisms for pan assay interference compounds toward promiscuous 
inhibition.  
Mechanism  Examples  Description  
Redox recyclers   Toxoflavin            Phenol-sulphonamides 
 
            
 
 
Compounds produce 
hydrogen peroxide 
which activates and 
inactivate different 
proteins and breaks 
down into molecules 
that give false 
signals. 
Covalent 
modification  
Curcumin                 Isothiazolones                               
 
                  
These compounds 
react chemically with 
proteins in a 
non-specific, non-
drug like way. They 
also disturb the 
response of 
membrane 
receptors. 
Metal complexation Hydroxyphenyl           Ene-rhodanine 
   
              
Compounds 
sequester metal ions 
that inactivates 
proteins. 
 Table information obtained from Baell and Walters, 2014.
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1.3.2.1. Redox recycling compounds  
Redox recycling compounds (RCCs), also known as redox recyclers, produce hydrogen 
peroxide in the presence of strong reducing agents such as dithiothreitol (DTT) (Figure 1.5) 
(Baell and Walters, 2014). In HTS assays, such reducing agents are common components 
found in assay or enzyme storage buffers used to maintain catalytic activity and/or folding of 
target proteins (Lor et al., 2007; Johnston et al., 2008; Soares et al., 2010). The hydrogen 
peroxide produced by RCCs oxidizes cysteine residues that are vital to keeping target proteins 
in their active form (Tierno et al., 2007; Baell and Walters, 2014). In search of compounds that 
inhibit caspase-8, Smith and co-workers conducted an HTS of more than 700,000 compounds 
which generated about 1% of HITS (Smith et al., 2002). However, 85% of the primary group 
of compounds tested were found to be RCCs as they inhibited the enzyme upon the production 
of hydrogen peroxide in the presence of the reducing agent DTT (Smith et al., 2002).   
 
 
 
Figure 1.5: The generation of hydrogen peroxide by redox recycling compounds in the presence 
of a reducing agent. Figure obtained from Johnston, 2011. 
1.3.2.2. Covalent modification  
Covalent modification occurs as result of the removal or attachment of a molecule to a protein 
or enzyme (Figure 1.6). Often, the contributing molecule provides a functional moiety that 
alters the function, catalytic activity and structure of the enzyme (Berg et al., 2002). 
Consequently, a new substrate might then be required for the modified enzyme. Covalent 
modification is an enzyme regulatory strategy that can be both irreversible and reversible 
(Hinman et al., 2006; Tizón et al., 2015). Examples of covalent modification include but not 
limited to phosphorylation and acetylation (Berg et al., 2002). Promiscuous compounds 
Epigallatocatchin-3-gallate (EGCG) and curcumin are amongst the compounds reported to
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interact with proteins through both covalent modification and redox recycling (Ishii et al., 2008; 
Baell and Walters, 2014; Farhan et al., 2016). 
 
Figure 1.6: An example of covalent modification of a protein by EGCG through autoxidation. 
Figure obtained from Ishii et al., 2008. 
1.4. Aggregate-based promiscuous compounds  
Of the known types of promiscuous compounds, aggregate-based compounds remain 
dominant. Despite their dominance, not much is known about aggregate structure, 
concentration, stoichiometry and even their affinity to targets remains inconclusive. However, 
it is common knowledge that these small molecules form colloids of 30-400 nm in diameter 
and their existence results in false positives in biochemical assays (Doak et al., 2010). As per 
their name, these microscopic molecules are formed by spontaneous self-association which 
leads to aggregation at micromolar concentrations in aqueous solutions (Doak et al., 2010). 
These molecules are problematic and are challenging to identify because they do not affect 
spectral assays, do not appear to be chemically reactive and they pass internal filters 
previously used to identify promiscuous compounds (Shoichet, 2004). The internal filters 
include interference with assay measurements such as absorbance and fluorescence; 
instability; reactivity and compounds that do not possess both oxygen and nitrogen which are 
considered to lack drug-ability (Bruns and Watson, 2012). Figure 1.7 shows a typical example 
of non-specific inhibition by aggregate forming compounds.
  
11 
 
               
Figure 1.7: Enzyme inhibition through aggregation. The process that results in the formation of the 
aggregates through self-association of single compounds which non-specifically inhibit the enzyme. 
1.4.1. Signatures of aggregate-forming compounds  
McGovern and colleagues were the first to identify aggregation as a mechanism for non-
specific inhibition (McGovern et al., 2002). Even though their initial intention was to identify 
inhibitors for β-lactamase, the compounds tested showed puzzling behaviours. Initially, these 
compounds were thought to interact through covalent inhibition, however, this speculation was 
soon rooted out since inhibition of these compounds showed to be reversible through dilution 
which is not a trait of covalent inhibitors (McGovern et al., 2002). Inhibition of three unrelated 
proteins, being non-competitive and steep dose-response curves were amongst the other odd 
behaviours identified in the tested compounds. In 2003, McGovern and co-workers further 
investigated 100 small compounds (including clinical drugs, leads and screening HITS) to 
further understand this mechanism for non-specific inhibition (McGovern et al., 2003). Of the 
compounds screened, approximately 50 were reported to show inhibition of various dissimilar 
enzymes in a time-dependent fashion (McGovern et al., 2003). These results led to the 
properties that help identify and distinguish the aggregate-forming inhibitors from well-
behaved inhibitors. The promiscuous inhibitors were found to be sensitive to detergents, ionic 
strength and enzyme concentration which was seen to be different for the well-behaved, or 
true inhibitors (McGovern et al., 2003). Table 1.2 shows various properties of aggregate-based 
promiscuous inhibitors and two of these properties (sensitivity to increased enzyme 
concentration and effect of incubation) are discussed briefly below. 
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1.4.2.  Sensitivity to increased protein concentration  
One of the well-known signatures of aggregate-based promiscuous compounds is their 
sensitivity towards changes in enzyme concentrations. In the work done by McGovern and co-
workers in 2002, they found that increasing the concentration of the enzyme or target resulted 
to a drastic decrease in inhibition effect of the aggregate based compound at micromolar 
concentrations (McGovern et al., 2002). Conversely, this was not the case with true or well-
behaved inhibitors, since increasing the protein concentration did not interfere with inhibition. 
Experimentally, testing for this feature can be done by performing a screening assay with an 
increased enzyme concentration (10-fold) (McGovern et al., 2002). Normally, this test is done 
with the inhibitor present at an inhibitory concentration 50% as determined by the same 
enzyme system before the increase in enzyme concentration.   
1.4.3. Effect of incubation time  
Inhibition by aggregate forming inhibitors increases when these compounds are pre-incubated 
with the enzyme 5 minutes before adding the substrate, which is different when compared to 
the same aggregate forming inhibitors without pre-incubation (McGovern et al., 2002). 
Incubation is reported to not be specific for the formation of aggregators since there are 
inhibitory mechanisms that operate in a time-dependent manner such as covalent binding 
(Alvarez and Shoichet, 2005). This effect can be tested by adding an incubation period to the 
protocol. If the inhibitor shows time dependence behavior, apparent inhibition should decrease 
in the absence of the incubation period. Normally, this assay is performed with the inhibitor at 
the IC50 concentration obtained in the typical assay of incubation (Alvarez and Shoichet, 2005). 
For aggregate inhibitors, the inhibition should decrease by 50% to about 40% without 
incubation. As a control well behaved, non-time dependent inhibitors of the target should not 
show an appropriate difference in inhibition with or without inhibition period.
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Table 1.2: Comparison of the typical behaviours of aggregate-forming inhibitors and well-
behaved inhibitors. 
Experimental features Aggregate-
based 
inhibitors  
Well-behaved 
inhibitors  
References  
Decreased inhibition in the 
presence of a detergent 
        X Feng and Shoichet, 2006 
Inhibition of unrelated 
enzymes 
        X Seidler et al., 2003 
Decreased inhibition in the 
presence of albumin 
  Occasionally Alvarez and Shoichet, 2005 
Inhibition in orthogonal 
assays  
      X   Thorne et al., 2010 
Decreased inhibition in the 
presence of increased 
enzyme concentration 
        X McGovern et al., 2002 
Formation of particles 
detectable by light 
scattering  
        X Seidler et al., 2003 
Inhibition of wild-type and 
mutant proteins  
        X Ravikumar et al., 2004 
Decreased inhibition in the 
presence of increased ionic 
strength 
  Occasionally McGovern et al., 2002 
Increased inhibition with 
incubation time 
  Occasionally McGovern et al., 2002 
 
1.4.4. Mechanism of interaction between aggregators and protein 
Although not much is known about how these aggregate inhibitors achieve their function, a 
number of possible mechanisms of action have been discussed (Coan et al., 2009). These 
include chemical reactivity, denaturing, sequestering, endpoint interference and restrained 
dynamics. This study will focus on three of these mechanisms and they are discussed below. 
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1.4.4.1.  Sequestering 
Enzyme or protein sequestering is one of the common mechanisms that result in promiscuous 
inhibition (McGovern et al., 2003). Sequestering occurs at certain conditions and specific 
micro-molar concentrations, where small molecules self-associate to form microscopic 
colloidal aggregate particles that are 30-400nm in diameter in aqueous solutions (Thorne et 
al., 2010). The aggregate forms colloids which cover or aggregate the enzyme thereby 
sequestering it from the reaction mixture (Figure 1.8C). It then appears as though the enzyme 
has been inhibited since its activity cannot be detected in the solution.  
1.4.4.2.  Enzyme unfolding and restrained dynamics 
When the aggregate-based inhibitors interact with the protein or the enzyme, a disruption of 
the protein's structure occurs. This disruption interferes with the function of proteins hence 
resulting in non-specific inhibition. In 2009, Coan and co-workers reported that the association 
of colloidal aggregate with an enzyme or protein might result to partial denaturing of the 
enzyme and this might be a possible inhibitory mechanism (Figure 1.8A) (Coan et al., 2009). 
Once the enzyme’s structure has been denatured or partially unfolded in the presence of the 
aggregate, it becomes less stable, leading to none or less activity. Hence, it appears as if the 
enzyme has been inhibited (Coan et al., 2009). Kinetic experiments have shown that solvent 
denaturants do not decrease potency or affect the aggregators (Coan et al., 2009). 
Additionally, other studies have shown that the decrease in thermodynamic stability of an 
enzyme does not increase the potency of aggregate-forming compounds (Coan et al., 2009). 
This mechanism is general since it does not require any specific feature of the aggregate 
structure or the enzyme. What this mechanism requires are non-polar residues (present in all 
enzymes) which associate with the non-polar surface of the aggregate inhibitors which is also 
always present. This explains the unselective and non-specific nature of aggregate inhibitors 
with soluble proteins. Another possible mechanism which is referred to as the restrained 
dynamic interaction is shown in Figure 1.8B. Instead of unfolding, the aggregate inhibitor might 
solidify the enzyme which restricts any possible movement. Therefore, the enzyme cannot 
interact or bind the inhibitor or substrate. Again, it will appear as though the enzyme is inhibited 
whereas its’ structure and hence activity are restrained.
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Figure 1.8: Three models of inhibitory mechanisms of aggregate-based promiscuous 
compounds. The promiscuous aggregate inhibitor (orange), interacts with the enzyme (blue ribbons) 
and the black arrows show how they proceed with the interaction. A. shows interaction with the 
aggregate can denature the protein leading to partial unfolding. B. shows the interaction with the 
enzyme restrains its dynamics and restricts its’ catalytic function. C. aggregates form colloids that 
sequester the enzyme. Figure obtained from Coan et al., 2009. 
1.4.5. Known compounds previously identified as aggregators  
Generally, aggregators are highly conjugated and hydrophobic molecules (Coan and 
Shoichet, 2008). However, predicting which compounds aggregate with a glance has proven 
to be difficult since aggregation depends on several factors such as pH, temperature, 
concentration and others listed in Table 1.2.
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1.4.5.1. Congo Red 
Congo Red is a benzidine-based stain that belongs to the family of Azo dyes (Figure 1.9). It is 
one of the first direct dyes which can have direct contact or can directly dye cotton without 
needing a fixation substance (Frid et al., 2007; Yaneva and Georgieva, 2012). This synthetic 
dye was first discovered in 1884 by Paul Böttiger, a young German scientist who first used it 
as a pH indicator (Steensma, 2001; Frid et al., 2007; Yaneva and Georgieva 2012). It was 
later that Congo Red was discovered to detect amyloid beta in cells since it binds and 
aggregates the beta conformation of the protein, this remained the major function of Congo 
Red in biochemical assays (Wood et al., 1983). However, recent studies showed that Congo 
Red binds to other proteins of different configuration and these proteins were unrelated 
(McGovern et al., 2002). This led to the conclusion that this dye resulted in non-specific 
binding, hence, it was identified as one of the promiscuous aggregate compounds. McGovern 
and colleagues demonstrated that the presence of Congo Red in biochemical assays 
aggregated proteins of unrelated natures such as chymotrypsin, β-lactamase and 
dihydrofolate reductase (McGovern et al., 2002). 
 
                                      
Figure 1.9: The chemical structure of Congo Red. The benzidine-based structure of Congo Red 
consisting of a hydrophobic center with two phenyl rings connected by diazo bonds. Figure was taken 
from Chowdhury and Bhattacharyya, 2015. 
1.4.6. Methods used to identify aggregate-based promiscuous compounds  
Due to their dominance and the identification properties mentioned above, aggregate forming 
inhibitors can be detected using a number of techniques and assays. Gurgen Tumanian, 
Allison Doak, Teague Sterling, John Irwin, and Brian Shoichet created Aggregate advisor 
which is a tool used to advise which compounds are likely to aggregate. Using conical SMILES 
of potential aggregators, aggregate advisor compares the structure of the compound with that 
of some known and previously identified aggregators (advisor.bkslab.org). Most identified 
aggregates are reported to be dye conjugated, examples of such are Congo Red and
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methylene blue (Bruns and Watson, 2012). Other techniques include; detergent based, 
dynamic light scattering and the Surface Plasmon Resonance assays. 
1.4.6.1. Detergent-based assays  
Promiscuous inhibitors are sensitive to detergents like Triton X100 (non-ionic), CHAPS 
(zwitterionic) and Tween 20 (non-ionic). This is due to the detergents’ ability to adjust the 
aggregation process of small molecules by decreasing their surface tension, this is an 
important factor used in the detection of these inhibitors (McGovern et al., 2002). Although 
this method is less direct than other methods that measure the physical formation of particles, 
it is more stable, requires less time and more susceptible to miniaturization (Feng and 
Shoichet, 2006). Feng and Shoichet reported that molecules whose inhibition is higher in the 
absence of detergents are likely to be inhibiting via the formation of promiscuous aggregate-
based inhibitors. They justified this by proving that in the presence of detergents the inhibition 
was decreased which means that the aggregate inhibitors were detected (Feng and Shoichet, 
2006). The level at which promiscuous inhibition is decreased depends on the type of 
compound, nature and the concentration of the detergent (Ryan et al., 2003). This is evident 
in an experiment conducted where two aggregate inhibitors (Congo Red and Rottlerin) were 
exposed to the presence of 0.02 CMC CHAPS, the Congo Red lost its inhibitory activity 
whereas the Rottlerin maintained some inhibitory effect (Ryan et al., 2003). Furthermore, when 
the same inhibitors were exposed to 0.02 CMC-Tween 20, Congo Red managed to retain its 
inhibitory whereas Rottlerin was no longer inhibitory (Ryan et al., 2003). 
1.4.6.2. Dynamic light scattering   
Dynamic light scattering (DSL) method is another alternative for the detergent-based assay 
and it is used to detect and quantify the size of micro-aggregates. The DLS technique involves 
determining the variation of scattering intensity of particles in solution that illuminate under a 
coherent light source over time (Chan et al., 2009). The DLS Plate Reader is the typical 
instrument used when examining the light scattering properties of a dilution series of known 
aggregating inhibitors. It is commonly seen that there is a direct proportionality between the 
compound concentration and the DLS instrument light scattering, however, when aggregating 
compounds are detected there is a dramatic decrease compared to the non-aggregating 
compounds. This method is reported to be more direct than the detergent-based assay (Feng 
and Shoichet, 2006). Conversely, it is a low throughput and detection takes a longer period of 
time. It is also not easy to interpret the measurements produced by DLS during the evaluation 
of insoluble compounds which leads to the formation of fit errors (Lorber et al., 2012). These 
errors are generated from the DLS particle-sizing model that is based on 
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Mie-theory calculation which takes on scattering from spherical particles of regular size. 
However, aggregates form inconsistent, irregular shapes of fibrous tendrils and uneven 
clumps. Chan and associates reported that even though DLS quantify the size of scattered 
particles in solution, it failed to characterize aggregation of the compounds in their experiment, 
which was seen by a noticeable difference in readings for each small molecule (Chan et al., 
2009).  
1.4.6.3. Surface plasmon resonance  
Surface Plasmon Resonance (SPR) assays are a common tool used to detect and 
characterize inhibitors involved in promiscuous binding and to determine the degree of 
interaction between aggregates and the protein (Karlsson, 2004). Therefore, aggregating 
compounds can be directly detected in SPR assays through an optical biosensor surface by 
monitoring the rate at which proteins interact with the small molecules in kinetic reactions 
(Chan et al., 2009). Furthermore, the use of this assay enables the differentiation between the 
compound aggregation and compound affinity. Additionally, the results obtained from the SPR 
provide other useful information about reversibility, stoichiometry, and alterations in the 
behaviour of compound over a series of concentrations (Giannetti et al., 2011).  
1.5. Thermal shift assays 
Thermal shift assays (TSA) is a collective term given to thermal denaturing methods in 
biochemical assays mostly used to study ligand binding to purified proteins. These biophysical 
techniques are inexpensive and present quick methods for measuring the thermal stability and 
transitions of proteins under different conditions (Niesen et al., 2007). The unfolding transitions 
of proteins are explored in a temperature gradient shown in a sigmoidal melting curve that 
deduces the melting temperature (Tm) of the protein. The ‘shift’ is then caused by the binding 
of a ligand to a protein which increases the Tm to a higher temperature, hence, resulting in a 
thermal shift. In drug discovery, the thermal shift assays are used for the identification of 
possible HITS and for low molecular molecule studies (Zubrienė et al., 2009). 
The thermal shift assays cover several approaches and applications of both high throughput 
and low throughput nature (Table 1.3) which are widely used in biochemical assays, structural 
biology and have contributed to drug discovery (Patel et al., 2008; Thompson et al., 2008). 
Traditionally, these assays employ temperature-regulated instruments such as real-time PCR 
machines, thermal cyclers or heating plate readers to monitor the changes in fluorescence, 
absorbance and circular dichromic (Chavan et al., 1994; Morton et al., 1995). The cell-based  
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thermal shift assay (CETSA) and the differential scanning fluorimetry (DSF) are the most used 
thermal shift methods and they are briefly discussed below. 
1.5.1. Cell-based thermal shift assays  
The CETSA method, first described in 2013 by Molina and co-workers is used for target 
engagement in drug discovery and it explores the principle that ligand binding relies on the 
stabilization of the bound protein (Molina et al., 2013). This principle is comparable to that of 
the traditional TSAs, however, CETSA is broader as it is applicable to living cells, cell lysates 
and tissues (Ishii et al., 2017). Following the discovery that several proteins unfold and 
precipitate in a similar manner as purified proteins when heated in cells, the CETSA approach 
quantifies the amount of soluble protein remaining in cells that have been heated at gradual 
temperatures in the presence or absence of a ligand (Molina et al., 2013; Molina and Nordlund, 
2016). The CETSA is a useful tool in a number of stages in the drug discovery pathway due 
to its versatility, it can also be used in HTS since it can be performed in a physiologically 
relevant context. 
1.5.2. Differential scanning fluorometry  
DSF, initially known as the Thermofluor is a high throughput method which monitors protein 
thermal denaturation by fluorescence, and it is conducted in real-time quantitative polymerase 
chain reaction (qPCR) machine (Senisterra et al., 2012; Huynh and Partch, 2015). As shown 
in Figure 1.10a, DSF experiments generally require a few reagents; protein; ligand; assay 
buffer and the dye, these reagents are all placed in a PCR tube at a total volume of 25 µL. 
During these assays, the protein solution is heated at a temperature gradient ranging from 25 
°C to 95 °C in the presence of environmentally sensitive dyes such as SYPRO Orange, 1-
anilinonaphenthalen-8-sulfonic acid (1, 8-ANS), 2, 6-ANS to name a few (Pantoliano et al., 
2001).  
The baseline temperature of 25 °C does not denature the protein, however, an increase in 
heating causes a change in the conformation of the protein. A further increase in temperature 
unfolds the protein thereby introducing hydrophobic regions in the solution. The dye which is 
attracted to the hydrophobic regions binds to the unfolded protein resulting in an increase in 
fluorescence (Vollrath et al., 2014). As shown in figure 1.10b, when the fluorescence 
increases, it allows the determination of the melting temperature (Tm) of the protein which is 
indicated as the midpoint of the peak (Lo et al., 2004). Once the melting temperature is 
reached, the dye is released into solution and protein is aggregated which causes a decrease 
in fluorescence as seen in Figure 1.10b.
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Figure 1.10: An illustration of the thermal shift assay. a), a typical example of sample preparation 
for the thermal shift assay. b) the thermal transitions of a protein showing three stages that take place 
during the temperature gradient; native, denaturation and aggregation. Figure obtained from Vollrath et 
al., 2014. 
 
Table 1.3: Different thermal shift methods and their applications  
Application Approach  Throughput  References  
Drug lead 
optimization  
DSC 
DSF  
Low 
Highest 
Matulis et al. ,2005; 
Srinivasan et al., 2015 
Enzyme mechanism DSF  Highest Lea and Simeonov, 
2012 
Parallel thermal shift 
assays  
CETSA Lowest   Molina et al., 2013 
Protein stabilization  DSF Highest Alexandrov et al., 2008  
Inhibitor screening  DSF Highest  Grüneberg et al., 2001; 
Grøftehauge et al., 
2015 
Assigning function of 
unknown proteins  
DSF Highest  Carver et al., 2005 
Protein-protein 
interaction  
DSF Highest  Kopec and Schneider, 
2011 
Mutation effects and 
characterization of 
variant proteins  
DSLS 
DSF  
Intermediate  
Highest  
Hong et al., 2007; Allali-
Hassani et al., 2009; 
Lavinder et al., 2009 
Antibody 
formulations  
DSLS   Intermediate  He et al., 2010; He et 
al., 2011 
DSF-Differential scanning fluorimetry; CETSA-Cell-based thermal shift assay; DSLS-Differential static 
light scattering; DSC-Differential scanning calometry.
m 
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1.6. Stem bromelain 
Bromelain is a non-toxic mixture of proteolytic enzymes present in the tissues of the pineapple 
plant and additional species of the family of Bromeliaceae (Hatano et al., 1998; Hale et al., 
2005). These enzymes were first identified in the fruit flesh in the early 1890s (Chittenden et 
al., 1891) and have since been known as fruit bromelain (EC 3.4.22.33). Following their 
identification in the 1950s, proteolytic enzymes found in the fruit stem have since been known 
as stem bromelain (EC 3.4.22.32) and determined as having higher bromelain activity than 
the fruit bromelain equivalent (Taussig and Batkin, 1988). This mixture contains thiol-
endopeptidases and many other non-characterised components such as peroxidases, 
phosphatase, carbohydrates and glycoproteins that do not exhibit proteolytic activity (Pavan 
et al., 2012).  
1.6.1. Properties of stem bromelain  
Commercially obtained bromelain is a yellow powder prepared by centrifugation, ultrafiltration, 
and lyophilization of cooled pineapple. Bromelain is approximately 33 kDa in molecular size 
and it is made up of 212 amino acids (Heinicke and Gortner, 1957). The enzyme activity of 
bromelain is determined with the specific substrates such as chromogenic tripeptides, casein, 
and gelatin. Bromelain is inhibited by N α (alpha)-Tosyl-L-lysine chloromethyl ketone (TPCK), 
trans-Epoxysuccinyl-L-leucylamido (4-guanidino) butane (E-64) protease inhibitor, 
iodoacetate and other elements such as silver, mercury and copper (Gautam et al., 2010). 
The non-toxicity and effectiveness of bromelain after being administered orally has allowed it 
to be used for a number of therapeutic functions.  
1.7. Hypothesis aim and objectives  
The hypothesis of this study was that the thermal shift assay could be used in a novel manner 
to identify aggregate-based promiscuous inhibitors. This study aimed to optimise a detergent-
based thermal shift assay using stem bromelain as a model enzyme.  
Objective 1: To isolate the enzyme bromelain in a mixture using molecular exclusion 
Chromatography. 
Objective 2: To determine the activity of bromelain using the titrimetric assay. 
Objective 3: To determine the temperature profile of bromelain and the effect of the inhibitor 
(E-64). 
Objective 4: To identify the effect of promiscuous compounds on the temperature profile of 
bromelain in the presence and the absence of the detergents.
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Chapter 2: Methods and materials 
 
2.1. Theoretical characterization of stem bromelain  
The amino acid sequence of stem bromelain was obtained from UniProt (www.unipot.org; 
accession number P14518. Molecular properties such as effective size, melting temperature, 
extinction coefficient were obtained from ExPASy (www.expasy.org). The hydrophobicity plots 
were also obtained from ExPASy (ProtParam) according to the Kyte and Doolittle scale (Kyte 
and Doolittle, 1982). 
2.2. Isolation of stem bromelain  
2.2.1. Separation of proteins through molecular exclusion chromatography 
Stem bromelain (Sigma, USA) was isolated by molecular exclusion chromatography (MEC) 
using the ÄKTAprime Plus fast protein liquid chromatography (FPLC) (GE Health Care 
Biosciences, Sweden). A 600 mm long column was packed with HiPrep 16/60 Sephacryl S200 
high resolution (HR) resin which has a fractionation range from 5 to 250 kDa. The resin was 
equilibrated as described in Eyssen, 2014, and the column was washed with 60 mL Milli-Q 
water followed by equilibration with MEC buffer (50 mM NaH2PO4, 300 mM NaCl pH 8). The 
flow rate was set at 0.5 mL / min with pressure at 0.30 MPa and the injection valve set to inject 
prior to the run. A total of 1 mL bromelain solution (200 mM in 100 mM sodium acetate buffer 
containing 260 mM sodium chloride at pH 4.5) was centrifuged using the bench top centrifuge 
for 20 minutes at 3000 x g and loaded in the column. The column was washed at a flow rate 
of 1 mL/ min with 0.2 M NaOH (60 mL) followed by MEC buffer (160 mL), Milli-Q water (60 
mL) and finally with 20% ethanol (120 mL).  
2.2.2. Sample concentrating  
Fractions containing peaks were pooled and concentrated through centrifugation at 6000 x g 
for 10 minutes and 4 °C in centrifugal filter units (Merck-Sigma, USA) with a 10 kDa cut off 
using a C0650 rotor in the Allegra x-22R centrifuge (Beckman Coulter, USA). The protein 
concentration of the pooled sample was determined using the NanoDrop (Thermo Fischer 
Scientific, USA) through the protein A280 option. Briefly, an amount of 2 µL of the elution 
buffer was used as a blank before measuring the protein concentration at the same volume.
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2.2.3. Separation by SDS-PAGE   
For the characterization of stem bromelain based on its size, SDS-PAGE was adopted. 
Freshly made reagents used in preparation of the gels that were made as per the Laemmli 
method (Laemmli, 1970). Briefly, 12.5% running gels were poured in between plates and left 
to polymerize for approximately an hour before pouring 4% stacking gels. The samples were 
run under non-reducing conditions. Precision Plus Protein Standards (Bio-Rad Laboratories, 
USA) were used as molecular weight markers and the run was completed at a constant current 
of 20 mA/ gel and at maximum voltage. The gels were stained with Coomassie Blue R-250 
(Sigma, USA) and de-stained with a methanol acetic acid solution. 
2.3. Evaluation of stem bromelain activity 
The activity of commercial bromelain was determined according to the titrimetric assay 
previously described by Gautam et al., 2010. Briefly, bromelain (Sigma, USA) at 
concentrations 2 and 4 units/ mg enzyme (2290 units = 1 g) was prepared in 100 mM sodium 
acetate buffer containing 260 mM sodium chloride at pH 4.5, and added to 5% gelatin (Sigma, 
USA) at a 1:25 ratio. This sample was incubated at 45 °C under non-shaking conditions for 20 
minutes followed by the addition of 0.1 mL of a 3% hydrogen peroxide (Merck-Sigma, USA). 
The pH was adjusted to 6.9 with 0.05 N sodium hydroxide (Acechem, RSA) and then mixed 
under constant swirling with 10 mL of the 37% formaldehyde (Merck-Sigma, USA). Thereafter 
the pH of this solution was adjusted to 7.8 using the 0.05 N sodium hydroxide (Merck-Sigma, 
USA). The volume of sodium hydroxide required to adjust the pH to 7.8 was recorded and this 
sample was designated as the test sample. The blank sample was run simultaneously with 
the test sample. Here, an amount of 25 mL of the gelatin solution was incubated at 45 °C for 
20 minutes. After incubation, 1 mL of the enzyme solution was added and mixed by swirling. 
To this, 0.1 mL hydrogen peroxide was added, and the pH was adjusted to 6.9 by titrating with 
0.05 N sodium hydroxide. An amount of 10 mL of 37% formaldehyde solution was added with 
constant swirling and the pH was finally adjusted to 7.8 using the sodium hydroxide solution. 
The volume required to adjust the control sample to pH 7.8 was recorded. The content of stem 
bromelain in solution was then calculated by means of the following equation (Gautam et al., 
2010): 
 
Units/mg enzyme = (Volume for Test - Volume for Blank) (N) (14) (1000)               
                                                 
                                            mg enzyme/RM 
 
Where: N= normality of sodium hydroxide,
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14 = mg nitrogen/ mmole nitrogen,  
1000 = milligram conversion,  
mg enzyme = amount o/gram of bromelain present in a 1 mL solution  
RM= reaction mix (for this experiment RM =1) 
Similarly, this assay was used to monitor the change in absorbance during the reaction using 
yellow-dyed gelatin. Absorbance readings were taken at each step of the assay on a Bio Wave 
DNA spectrophotometer (Biochrom, UK) over a wavelength range of 300 – 500 nm.  The 
enzyme activity was calculated in Gelatin digestive units (GDUs). 
2.4. Radial diffusion assays  
The radial diffusion assays were carried out as previously described in Gallagher et al., 1986. 
The activators (cysteine, Ethylenediaminetetraacetic acid (EDTA) and soybean trypsin 
inhibitor (Sigma, USA)), inhibitors (E-64, iodoacetate (Sigma, USA), and mercury) and 
compounds (Congo Red and EGCG (Sigma, USA)) were dissolved in distilled water and the 
Bromelain solution in the assay buffer. The 1% (m/v) agarose containing 0.1% gelatin was 
prepared through dissolving the agarose in assay buffer (100 mM sodium acetate buffer 
containing 260 mM sodium chloride at pH 4.5) then heating it in a microwave for complete 
dissolution. The gelatin solution prepared in distilled water was added to the liquefied agarose 
and mixed in a flask through gentle shaking. The agarose- gelatin solution was poured into a 
petri dish and allowed to solidify, the wells were punched in using a syringe leaving 0.5 cm 
between them.   
An amount of 25 µL of the protein solution was added to 15 tubes marked E1 – E15, a further 
25 µL of the assay buffer was added to tube E1 and E6 and to the rest of the tubes 25 µL of 
assay buffer containing 40 mM cysteine. All the tubes were incubated at 37 °C for 5 minutes 
in a water bath, 50 µL of assay buffer, assay buffer with cysteine, EDTA (200 mM), iodoacetate 
(100 mM), soybean trypsin inhibitor (100 mM), mercury (1.5 mg/ mL), EGCG (0.008 mM, 0.009 
mM, 0.01 mM and 0.015 mM ), Congo Red (0.008 mM, 0.009 mM, 0.01 mM and 0.015 mM ) 
and E-64 (0.030 mM) were added to tubes E1 – E15 respectively. The tubes were further 
incubated for 15 minutes at 37 ºC in a water bath and the solutions in each tube was used to 
fill up respective wells on the agarose-gelatin in a petri dish. The petri dish was placed in a 
plastic container based with a damp paper towel and incubated at room temperature overnight. 
The solid gel was stained using 1% Amido black dissolved in the distaining solution for nor 
less than 5 hours before distaining with a methanol-acetic acid-distilled water solution for 24 
hours changing the distain at least 3 times. 
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2.5. Thermal shift assays  
All thermal shift assays were run using qPCR clear tubes on the real time PCR machine 
(Corbett 5 Plex high resolution melt (HRM), Corbett, Australia) at a temperature profile of 25 
to 95 °C with temperature increment increases of 0.2 °C, holding time of 2 seconds and the 
gain held at 7 as instructed in Niesen et al., 2007. The SYPRO orange dye (Thermo Fisher 
Scientific, USA) at 10X concentration was prepared fresh each time before use in a phosphate 
buffered saline (PBS) at pH 7.2. Stem bromelain solutions were prepared in a 100 mM sodium 
acetate buffer containing 260 mM sodium chloride at pH 4.5 and the protein concentration 
was confirmed each time using the NanoDrop (Thermo Fischer Scientific, USA). The inhibitors 
and compounds were prepared in dH2O at 125 µM stock solutions. 
2.5.1. Optimisation of dye concentration  
For optimisation purposes, using the same assay buffer used in the titrimetric assay, different 
concentrations of SYPRO Orange dye were tested to find a suitable concentration for the 
protein and the assay. A stock of 5000X dye concentration was diluted using PBS pH 7.2 to a 
stock of 200X and concentrations of 10 to 80X with 10X increments were analysed in the 
assay. These concentrations were tested in the presence and the absence of 17 µg/ 25 µL 
stem bromelain. The reagents were added in the following manner to make a total volume of 
25 µL; protein, assay buffer followed by the dye solution at a specific concentration. 
2.5.2. Optimisation of protein concentration  
Different concentrations of stem bromelain were subjected to the thermal shift assay for 
optimisation purposes as previously done in Vedadi et al., 2006. Once the concentration of 
the protein was confirmed using the NanoDrop, the solution was diluted into different 
concentrations of 5 to 29 µg/ 25 µL with 3 µg increments in triplicates at least five times. The 
samples were run in the presence of a final concentration of 10X SYPRO Orange and the 
reagents were added in a comparable manner as seen in section 2.5.1. The controls for these 
experiments were run either in the absence of dye or in the absence of the protein.  
2.5.3. The effect of inhibitors on stem bromelain 
Different concentrations of the protease inhibitors; E-64, iodoacetate and TPCK (Sigma, USA) 
were compared with stem bromelain at different concentrations in the thermal shift assay for 
optimisation purposes. The inhibitors were prepared in dH2O and kept on ice. Concentrations 
of 29, 17 and 5 µg/ 25 µL stem bromelain were tested against 5-50 µM of the inhibitors. The 
reaction mixture containing the protein, assay buffer, the inhibitor was 
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incubated for 30 minutes on ice while shaking. After the incubation SYPRO orange dye was 
added at a final concentration of 10X dye and the samples were run under optimized 
conditions. 
2.5.4. The effect of compounds on stem bromelain  
Congo Red and EGCG were dissolved in dH2O at a stock concentration of 125 µM and the 
solution was kept at room temperature and was made fresh each time for use. Concentrations 
of 5 to 20 µM with 1 µM increments Congo Red were tested in the presence of 5, 17 and 29 
µg/ 25 µL stem bromelain in the manner previously describe in section 2.5.3, similarly different 
protein concentrations were also tested with just one concentration of Congo Red. EGCG was 
tested in a comparable manner. 
2.5.5.  Identification of promiscuous compounds  
2.5.5.1. The protein-inhibitor and compound cocktail  
Stem bromelain was tested with both the inhibitor and the compound present in the same 
tube, the experiments were run comparably with all the thermal shift assays with an exception 
that in this section the reagents were added as follows; stem bromelain, inhibitor, compound, 
buffer, thirty minutes incubation and thereafter the SYPRO orange dye prior run.  
2.5.5.2. The dye aggregation principle  
The protein was tested on its own, in the presence of the inhibitor, Congo Red and EGCG and 
the experiments were run as seen in sections 2.5.4 corresponding to each compound and 
inhibitor. After the run the samples were cooled on ice for five minutes before the addition of 
protein in all the tubes, these experiments were done in triplicates at least five times. 
2.5.6. Optimisation of different detergents  
The detergents Tween-20 (Sigma, USA), Triton-X100 (Sigma, USA) and SDS (Sigma, USA) 
were diluted to a stock of 1% using distilled water and stored at room temperature in a Para 
film sealed tube. Different concentrations 0.002%, 0.004%, 0.006%, 0.008%, 0.01 and 0.012% 
of each detergent were tested in the thermal shift assay and the reagents were added in the 
following pattern; detergent (in a specific concentration), assay buffer and the dye.  
The protein was incubated with the detergent for approximately thirty minutes on ice before 
starting the reactions. The protein- detergent mixture was added first into the tube, followed 
by the inhibitor or the compound, the samples were then incubated for thirty minutes before
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the addition of the dye. These experiments were tested in the presence and in the absence of 
the detergents. 
2.6. Cytotoxicity assays 
2.6.1. Cell culture  
Human embryonic kidney 293 cells containing the SV40 T-antigen (HEK 293T cells) (Creative 
biogene, USA) were seeded in Dulbecco’s Modified Eagle’s Medium (DMEM) (Bio Whittaker, 
USA) containing 10% fetal bovine serum (FBS), 0.1% Penicillin streptomycin (x100) and 0.1% 
Gentamycin. The cells were maintained at 37 °C 5% carbon dioxide (CO2) humidified incubator 
for 72 hours and grown in T75 culture flasks. Trypsinization to harvest cells after achieving 
confluence was routinely achieved by resuspending cells in trypsin (10x) followed by a 2 
minutes incubation before adding an equal amount of DMEM medium. The cells were 
centrifuged at 200 x g for 5 min and pellet re-suspended in DMEM media by gently mixing to 
ensure solubility. Cell count was achieved by diluting cells with 0.4% Trypan Blue stain (Bio-
Rad, USA) at a 1:1 ratio and counting which was completed on a T20 Automated Cell Counter 
(Bio-Rad, USA). The final cell concentration of 1 x 105 cells / mL was cultured in 15 mL DMEM 
media. 
2.6.2. MTT assay  
The Cytotoxicity effect of Congo Red and EGCG on HEK 293T cells was evaluated through 
the MTT (3-4,5 dimethylthioazol-2,5 diphenyl tetrazolium bromide) assay as described in Leila 
et al., 2016. Briefly, the cells were seeded at a concentration of 1 x 104 cells/ mL per well in a 
96-well cell culture plate at a final cell volume of 100 µL per well and equilibrated at 37°C in 
an incubator of 5% CO2 for 2 hours. Congo Red and EGCG were diluted in DMEM medium 
and used to treat the cells at different concentrations (0-200 µM). After the two-hour 
incubation, 100 µL of each dilution was pipetted into the wells while controls were not treated, 
and the plate was further incubated for 72 hours. After treatment 20 µL of MTT (Sigma, USA) 
(5 mg/ mL) solution was pipetted into each well and the plate was incubated for a further 2 
hours in the 37°C and 5% CO2 incubator. After incubation, the supernatant was discarded by 
overturning the plate. An amount of 200 µL of solvents SDS (10%); SDS (10%)/HCL (0.01 M) 
and SDS (10%)/ HCL (0.01M)/ Isopropanol (200 µL) was added to respective wells to dissolve 
formazan crystals. The absorbance was read at 590 nm using microplate reader. Data 
analysis was completed using GraphPad prism 7 where the halfway maximal cytotoxicity 
concentration CC50 was determined as the compound concentration that would reduce the cell 
viability by 50%. The cell viability was taken as the absorbance of the untreated cells at 100%. 
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2.7. Statistical analysis 
All the Data collected was analyzed on GraphPad Prism 7 (GraphPad Prism, USA). Each 
experiment was presented in triplicates (n=3) and repeated at least five times. Statistical 
analyses were obtained from GraphPad Prism. The standard deviations are presented as error 
bars.
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Chapter 3: Results 
3.1. In silico theoretical analysis of stem bromelain  
The theoretical physiological analysis of stem bromelain is shown in Figure 3.1. Stem 
bromelain is comprised of 212 amino acid residues and is 33 kDa in size as per previous 
reports (Margaretta et al., 2015; Ritonja et al., 1989). Furthermore, the theoretical melting 
temperature (Tm) of stem bromelain is reported to be subject to pH (Haq et al., 2005). Where 
at neutral pH the melting temperature is 71 °C and at acidic pH it is 77 °C (Figure 3.1a). The 
amino acid sequence of stem bromelain contains an equal amount of hydrophilic and 
hydrophobic amino acid residues. This observation corresponded with the hydrophobicity plot 
of stem bromelain shown in Figure 3.1b. As seen in this plot, an evident percentage of the 
hydrophobic residues (Indicated by positive scores) was observed on the surface of the 
protein. Briefly, positions 5-45 and 180-200 have the highest hydrophobicity score of 1.5 to 2 
as previously analysed in Albee et al., 1997. An equal distribution of hydrophobic and 
hydrophilic amino acids was observed at the core of the protein (position 70-160).  
                                                                                                    
                             
 
Figure 3.1: Theoretical characterisation of stem bromelain including a) the molecular properties of 
stem bromelain and b) hydrophobicity plot of stem bromelain as obtained from www.expasy.org. 
3.2. Biochemical characterization of stem bromelain 
3.2.1. Isolation of stem bromelain 
As stem bromelain is a crude mixture of proteins, molecular exclusion chromatography was 
conducted to separate proteins in the mixture. An elution profile of stem bromelain with 
Properties Stem 
bromelain 
EC number 3.4.22.32 
Number of 
amino acids  
212 
Molecular 
weight 
33 kDa 
Melting 
temperature  
71 °C 1 
77 °C 2 
Theoretical PI 8.60 
a  b 
 1 Basic pH      2 Acidic pH 
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corresponding absorbances at 280 nm is shown in Figure 3.2. As seen in this figure, the first 
peak elutes at approximately 70 mL at an absorbance of 1250 mAu. A second peak, 
shouldering on the first peak is observed at approximately 120 mL with an absorbance of 600 
mAu. Finally, a broad, shallow peak elutes at 200 mL with absorbance maxima of 300 mAu. 
Fractions comprising of each of the peaks were pooled.  
0 1 0 0 2 0 0 3 0 0
0
5 0 0
1 0 0 0
1 5 0 0
V o lu m e  (m L )
m
A
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Figure 3.2: The molecular exclusion chromatographic (MEC) profile of bromelain mixture. 
Bromelain at a concentration of 200 mM was prepared in 100 mM sodium acetate buffer containing 260 
mM sodium chloride at pH 4.5. The sample was run in a 600 mm column packed with HiPrep 16/60 
Sephacryl S200 HR resin on an ÄKTA Plus purifier. The samples were eluted in the presence of MEC 
buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8) at a rate of 0.5 mL per minute. The two black arrows are 
an indication of the two peaks eluted at 70 mL and 120 mL.  
3.2.2. Separation by SDS-PAGE  
Following MEC, the pooled samples were concentrated using a 10 kDa centrifugation filter 
and separated by SDS-PAGE. Crude stem bromelain was observed to be a mixture, as 
separation resulted in five protein bands of different sizes and intensity (Figure 3.3). The first 
band was intense and observed at approximately 158 kDa, while less intense bands were 
observed at 33.11 kDa and 25 kDa. The fourth band observed at 15.6 kDa was narrow and 
less intense while the fifth band at 10.84 kDa was intense. A comparable SDS-PAGE analysis 
of extracted stem bromelain conducted by Gautam and colleagues yielded proteins of similar
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sizes (Gautam et al., 2010). Pooled samples from peak 1 were collected in the filter unit 
(concentrate) and in the wash-through (filtrate) of the centrifugal filter and their separation is 
shown in lanes 3 and 4 of Figure 3.3 respectively.  
The concentrate separated into three distinct protein bands at 33.11 kDa, 15.6 kDa and 10 
kDa while no protein bands were detected in the filtrate (lane 4). Similarly, the concentrate for 
peak 2 separated into four distinct bands at 33.11 kDa, 26,25 kDa and 22 kDa (lane 5) while 
the filtrate contained no protein bands (lane 6). Proteins at 33.11 kDa, 15.6 kDa and 10.84 
kDa present in peak 1 may have co-eluted in a complex or in an aggregate. It is likely that the 
> 200 kDa band observed in the crude mixture eluted in the void of the column. 
 
               
Figure 3.3: Analysis of bromelain samples separated on a 12.5% non-reducing SDS PAGE. All 
samples were loaded at 10 µL. Lane 1 is Precision Protein Plus Standards (250 – 10 kDa), lane 2 is a 
bromelain mixture (13 mM) prepared in phosphate buffered saline. Lane 3 and 4 are the concentrate 
and filtrate of the pooled fractions of peak of the MEC elution respectively, following centrifugal 
concentration. Similarly, lane 5 and 6 represent the concentrate and filtrate of the pooled fractions of 
peak 2 respectively following centrifugal concentration. The gel was run at 20 mA/ gel and stained with 
Coomassie Brilliant Blue. 
 
3.3. Enzyme activity  
3.3.1. Enzyme activity through gelatin digestive units  
The enzymatic activity of stem bromelain was demonstrated through the titrimetric assay 
shown in Table 3.1. The assay monitors the degradation of the substrate gelatin as measured 
in gelatin digestive units (GDUs). The activity in GDUs was then calculated from the volume
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of sodium hydroxide required to adjust the pH of the enzyme reaction mixture to pH 7.8. The 
2-unit enzyme required over 0.6 mL more hydrogen peroxide to reach the required pH when 
compared with the 4-unit enzyme (Table 3.1). Since no purification tests were conducted for 
this experiment, the reaction mixture was set to be 1 rpm for both the 4 and 2-unit enzyme. 
Therefore at 1 rpm, the 2-units enzyme yielded 2085.5 GDU / mg enzyme whereas the 4-unit 
enzyme yielded 2024.36 GDU/ mg enzyme. This was found to be comparable with previous 
reports (Gautam et al., 2010). 
Table 3.1: The titration volume of sodium hydroxide required to adjust the pH to 7.8 during 
the degradation of gelatin by 2-units and 4-units of bromelain enzyme.  
 2-unit enzyme 4-unit enzyme 
Blank  
(mL) 
Test  
(mL) 
Blank 
(mL) 
Test  
(mL) 
Volume of sodium 
hydroxide 
13.600 
13.460 
13.640 
13.120 
13.600 
14.700 
14.780 
15.000 
14.820 
14.600 
12.900 
12.740 
13.000 
12.860 
12.660 
14.000 
14.040 
14.060 
14.150 
14.200 
Average  13.484 14.780 12.832 14.090 
Standard deviation  0.192 0.133267 0.119733 0.073756 
 GDUs /mg enzyme 2085.5 2024.36 
 
 
3.3.2. The activity of bromelain through absorbance in the titrimetric assay  
The activity of stem bromelain was further investigated through absorbance in the titrimetric 
assay as shown in Figure 3.4. Commercial gelatin produced no peaks on the spectrum and 
as a result yellow coloured gelatin was used for this experiment. Unlike commercial gelatin 
(see Table 3.1), less volume of sodium hydroxide was required to adjust the test and blank 
solutions to pH 7.8 in the presence of 4-unit enzyme and yellow coloured gelatin. Even with 
this divergence, the pattern shown in Table 3.1 was still maintained in the presence of coloured 
gelatin. The blank solution required less volume (2.5 mL) than the test solution (3.6 mL) to 
adjust the pH to 7.8. The activity of stem bromelain in GDUs was calculated to be 1770.11 
units / mg enzyme. This notable decrease in activity was expected due to low volumes of 
sodium hydroxide titrated. The effect of each step of the assay is shown in Figure 3.4 where 
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notable shouldering peaks are observed at 420 and 435 nm. With reference to Figure 3.4, 
incubation at 45 °C and the addition of hydrogen peroxide had no effect on the assay. The 
same trend was observed in panel a, b and c. In these panels, the enzyme activity was higher 
for samples with stem bromelain (test) than the gelatin solution without enzyme (blank). 
However, the addition of sodium hydroxide decreased the activity of the test while increasing 
the activity of the blank with a notably enlarged difference in absorbance between them (Panel 
d). This trend was maintained in panel e and f, however further decrease in absorbance was 
observed upon the addition of formaldehyde and with the final titration with sodium hydroxide 
(panel e and f respectively).
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Figure 3.4: The absorbance profile of gelatin degradation in the bromelain titrimetric assay. The 
absorbance profile of yellow-dyed gelatin was tracked using the titrimetric assay in the presence of 4-
unit bromelain enzyme (red) and absence of enzyme (green). Panel a is the absorbance profile before 
incubation at 45°C, panel b was taken after incubation at 45°C for 20 minutes, panel c was taken after 
the addition of 3% hydrogen peroxide, panel d represents the first titration to adjust solutions to pH 6.9, 
panel e shows the effect of formaldehyde within the solution and panel f shows the final titration to pH 
7.8.
a b 
c d 
e f 
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3.4. The effect of compounds on the activity of stem bromelain  
The activation and inhibition of stem bromelain was studied on an agarose-gelatin diffusion 
assay. Table 3.2 lists the compounds that brought about inhibition or activation (no effect) of 
the enzyme. The list includes known promiscuous inhibitors Congo Red and EGCG which 
were tested at different low micro molar concentrations as previously advised (Heiser et al., 
2000; Necula et al., 2007; Sehm et al., 2015). The inhibition and digestion are demonstrated 
by the zone of each well (Figure 3.5). With reference to Figure 3.5, the presence of a clear 
zone indicated digestion of gelatin (activation of enzyme) and the absence of it demonstrated 
the inhibition of the enzyme by the compound added (Gallagher et al., 1986). Therefore, the 
compounds that had no effect on stem bromelain (activators) in this experiment were EGCG, 
Congo Red, cysteine, EDTA and soybean trypsin inhibitor, as cleared zones were observed 
in these wells (Figure 3.5). Conversely, the enzyme was inhibited by iodoacetate, E-64 and 
mercury as stated in Table 3.2 and evident with the lack of cleared zones in Figure 3.5. 
Inhibition of stem bromelain by these inhibitors in different assays is reported in Chao and 
Liener., 1967; López‐García et al., 2012; Masdor, 2013. 
 
Table 3.2: The effect of inhibitors and activators in the digestion of an agarose-gelatin gel in 
the presence of stem bromelain. 
Well number  Compound name  Digestion  Inhibition  
1 Buffer         x  
2 Buffer with cysteine         X 
3 EDTA         X 
4 Iodoacetate       x   
5 Soybean trypsin   
inhibitor 
        X 
6 Mercury       x   
7-10 EGCG     
11-14 Congo Red         x 
15 E-64       x   
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Furthermore, the cleared zones observed differed in intensity, with Congo Red having the 
lightest wells at concentrations 0.009 mM, 0.010 mM and 0.015 mM, whereas cysteine has 
the darkest zoned well. Figure 3.6 quantifies the degree of bromelain inhibition by each 
compound through measuring the distance travelled by the cleared zone in mm. Congo Red 
travelled the longest distance (30 mm) whereas the shortest distance was travelled by mercury 
(0 mm). Granting that wells 7-10 contained EGCG, they were however observed to have 
travelled different distances (Figure 3.6). The inhibitors iodoacetate and E-64 both travelled 
0.5 mm which shows that they did not completely supress the activity of the enzyme whereas 
mercury completely inhibited stem bromelain activity (distance 0 mm). 
 
    
Figure 3.5: The digestion of gelatin by bromelain in the presence of activators, inhibitors and 
compounds. An amount of 25 μL bromelain 0.3 mg/ mL bromelain stock was incubated with 50 μL of 
cysteine, EDTA (100 mM), iodoacetate (100 mM), soybean trypsin inhibitor (100 mM), Mercury (1.5 mg/ 
mL) Congo Red (8, 9, 10, and 15 μM), EGCG (8, 9, 10 and 15 μM) and E-64 (0.030 mM) in 1% agarose 
containing 0.1% gelatin gel and further incubated overnight. The gel was stained using a 0.15% Amido 
black solution and de-stained with a methanol-acetic acid-water solution. 
1- Buffer 
2- Buffer with Cysteine  
3- EDTA (20 mM) 
4- Iodoacetate (100 mM) 
5- Soybean trypsin inhibitor (100 
mM) 
6- Mercury (1.5 mg/ mL) 
7- EGCG (0.008 mM)  
8- EGCG (0.009 mM)  
9- EGCG (0.010 mM)  
10- EGCG (0.015 mM)  
11- Congo Red (0.008 mM)  
12- Congo Red (0.009 mM) 
13- Congo Red (0.010 mM) 
14- Congo Red (0.015 mM) 
15- E-64 (0.030 mM)  
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Figure 3.6: The activation and inhibition of stem bromelain in an agarose-gelatin gel. The distance 
(mm) travelled by the cleared zone measured across the diameter of the well after staining with Amido 
black. 
3.5. The thermal stability of stem bromelain  
3.5.1. Optimisation of dye concentration   
Thermal shift studies were achieved through the DSF assay which uses fluorescent dyes such 
as SYPRO orange to monitor the transitions in the signal as the protein undergoes thermal 
unfolding. Hence, optimisation of a suitable dye concentration was considered as a crucial 
step in this study. The effect of eight different concentrations of SYPRO orange dye on the 
thermal unfolding of stem bromelain is shown in Figure 3.7. A general downward trend (shown 
by a black arrow) was observed at low temperatures of the thermal profile for both the 
fluorescence intensity curve (panel a) and the derivative curve (panel b). Following this trend, 
a plateau was observed which peaked at 75-76 °C (Figure 3.7). The different concentrations 
of dye follow this trend, however, differ in fluorescence intensity as in previous reports 
(Niedziela-Majka et al., 2015). Notably, the dye-protein relationship was observed as inversely 
proportional since the peaks increased with a decrease in dye concentration. With 80X dye 
having the lowest or no peak and 10X dye with the highest peak. In 2015, Niedziela-Majka 
and colleagues reported that 10X dye concentration also gave the highest peak in the 
presence of 0.005% protein. However, a decrease in this concentration showed a decrease 
in the fluorescence intensity which contradicted with the results obtained in this study. To 
further investigate this, different concentrations of dye were compared with different 
concentrations of stem bromelain (results not shown). An inversely proportional relationship
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between the dye and the protein was still maintained and visible in fluorescent peaks. 
Therefore, from here on 10X dye concentration was regarded as an ideal concentration for 
this study.  
 
 
 
 
 
               
 
 
 
Figure 3.7: Optimization of SYPRO orange dye concentration in the presence of a fixed protein 
concentration. SYPRO orange dye was prepared in PBS pH 7.2 and was tested in the presence and 
the absence of a 17 µg / 25 µL of stem bromelain. Panels a and b represent the fluorescence and 
derivative curve respectively. The general downward trend is indicated by the black arrow. The 
temperature range was set at 25-95°C with temperature increment of 0.2 °C, holding time of 2 seconds 
and the gain held at 7.  
3.5.2. Optimization of protein concentration 
Different concentrations of stem bromelain were subjected to the DSF assay to assist in 
determining the melting temperature of stem bromelain. Generally, in thermal shift assays, the 
Tm is indicated as the halfway point of the apex in the fluorescence intensity curve (panel a) 
while in the first derivative plot (panel b) it is known as the highest point of the peak. The Tm 
of stem bromelain was observed to be at ~75-76 °C and was not affected by the change in 
protein concentration (Figure 3.8). However, the fluorescence intensity was observed to 
increase with an increase in protein concentration.  As a result of increased fluorescence 
intensity, the peaks were observed to be sharper and more defined (see Figure 3.8). 
Comparably, in previous studies, the Tm of proteins remained the same for all protein 
concentrations tested (Pantoliano et al., 2001; Vedadi et al., 2006; Niesen et al., 2007; 
Lavinder et al., 2009). 
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Figure 3.8: The unfolding transitions of stem bromelain at different concentrations in the 
presence of SYPRO orange dye.  Stem bromelain was prepared in a 100 mM sodium acetate buffer 
containing 260 mM sodium chloride at pH 4.5. The SYPRO orange dye was present at a final 
concentration of 10X in the respective tubes. Each PCR tube contained a solution with 25 µL final 
concentration and was prepared in the following order; protein at a specific concentration, the assay 
buffer and lastly the SYPRO orange dye. Panel a and b represent the fluorescence curve and the first 
derivative curve respectively. The black vertical line represents the Tm also known as the melting 
temperature. The temperature range was set at 25-95 °C with temperature increments of 0.2 °C, holding 
time of 2 seconds and the gain held at 7. 
3.5.3. The shift in the Tm of stem bromelain in the presence of E-64 
DSF assays containing E-64, a true inhibitor of stem bromelain, were conducted in a dose-
dependent manner. To cover the ranges, the inhibitor was tested in the presence of two 
different protein concentrations (17 and 29 µg / 25 µL). The Tm of stem bromelain was 
observed to be ~75-76 °C in the absence of the inhibitor but was increased to be ~84-86 °C 
in the presence of E-64, a ~9 °C shift to the right (Figure 3.9). Generally, the average shift 
upon ligand binding is known to be ~7 °C (Bia et al., 2019). Hence, the shift (~9 °C) obtained 
in this study was observed to be above this average. The p-value was between these two 
variants (protein and protein + inhibitor) was found to be 0.004963 which showed significance 
at p < 0.05. The effect of E-64 was observed to be moderately similar for each protein 
concentration with an exception for lower concentrations (5 and 10 µM) which showed no 
apparent effect (Figure 3.8). 
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Furthermore, sharper and more defined peaks were observed in the presence of higher 
concentrations of E-64. Besides the increase in fluorescence intensity, there was no prominent 
difference observed between the 17 and 29 µg / 25 µL thermal profiles (Figure 3.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: The effect of different concentrations of E-64 on different concentrations of stem 
bromelain. The inhibitor E-64 was dissolved in distilled water and tested at different concentrations in 
the presence of (i) 17 and (ii) 29 µg / 25 µL stem bromelain. Incubation of samples in ice was set for 30 
minutes before adding SYPRO orange dye at a final concentration of 10X. Panel a and b represent the 
fluorescence curve and the first derivative curve respectively; the black vertical lines indicate the Tm. 
The temperature range was set at 25-95 °C with a temperature increment of 0.2 °C, holding time of 2 
seconds and the gain held at 7.
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3.5.4. The effect of Congo Red on the unfolding transitions of stem bromelain  
The effect of the known promiscuous compound, Congo Red, on the melting profile of stem 
bromelain was evaluated in a similar manner as done for E-64 in the DSF thermal shift assay. 
The Tm of ~75-76 °C of stem bromelain was maintained in the presence of different 
concentrations of Congo Red. However, at protein concentrations 17 and 5 µg / 25 µL the 
effect of the compound was slightly different (Figure 3.10). A minor shift to the left was 
observed which appeared to be more prominent as the protein concentration decreased (see 
Figure 3.10 ii) and iii). Additionally, the presence of Congo Red was observed to decrease the 
fluorescence intensity in the thermal curve of stem bromelain. This was evident by low peaks 
which decreased with an increase in Congo Red concentration at all three tested protein 
concentration. Furthermore, this effect by Congo Red was observed to not only be dependent 
on the compound concentration but also highly dependent on the protein concentration. These 
results were expected as concentration dependent aggregation of proteins by promiscuous 
inhibitors have been reported (McGovern et al., 2002).
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Figure 3.10: The unfolding transitions of stem bromelain in the presence of different 
concentrations of Congo Red. The aggregate promiscuous compound was dissolved in water and 
tested at low micromolar concentrations in a 25 µL solution consisting of the protein, buffer and the dye 
added after a 30 minutes incubation. Different concentrations of Congo Red were tested in the presence 
of i) 29, ii) 17 and iii) 5 µg / 25 µL stem bromelain respectively. Panel a and b represent the fluorescence 
curve and the first derivative curve respectively, while the Tm is indicated by the black vertical line. The 
temperature range was set at 25-95 °C with temperature increment of 0.2 °C, holding time of 2 seconds 
and the gain held at 7. 
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3.5.5. The effect of the compound EGCG 
The compound EGCG was observed to have a different effect on stem bromelain when 
compared with Congo Red and E-64. Two shouldering peaks were observed in the presence 
of tested concentrations of EGCG which resulted in two different melting temperatures. As 
shown in Figure 3.11, the first peak was observed at ~75-76 °C and is identical to that of stem 
bromelain when tested on its own.  
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Figure 3.11: The unfolding transitions of stem bromelain in the presence of different 
concentrations of EGCG. EGCG was dissolved in water and tested at different concentrations in a 25 
µL solution consisting of the protein, buffer and the dye added after a 30 minutes incubation. The 
symbols i) and ii) represent concentrations 29 and 17 µg/25 µL stem bromelain respectively. With panel 
a and b representing the fluorescence curve and the derivative curve respectively. The temperature 
range was set at 25-95 °C with temperature increment of 0.2 °C, holding time of 2 seconds and the gain 
held at 7.
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The second peak was shifted to the right and was observed at ~87-88°C. However, at higher 
concentrations (35 µM) of EGCG the first peak was observed to fade while the second peak 
became dominant (Figure 3.11). Furthermore, the presence of EGCG resulted in low peaks 
when compared with the peak for stem bromelain in the absence of the compound. This 
decrease in fluorescence intensity was observed to be dependent on the concentration of 
EGCG, with 35 µM having the lowest peak while 10 µM had the highest peak at all tested 
protein concentrations (Figure 3.11).  
3.5.6. Aggregation vs. unfolding  
Up to this point, this study has explored the effect of compounds EGCG and Congo Red on 
the enzyme stem bromelain. However, the effect of these compounds on a stabilized protein-
inhibitor complex had not been explored. Therefore, the effect of compounds on a stabilised 
complex (protein-E-64 complex) was studied to understand the mechanism of action of 
compounds EGCG and Congo Red. With reference to Figure 3.12, Congo Red maintained its 
mechanism of action since stem bromelain was aggregated in the presence and in the 
absence of E-64. Even with this observed aggregation, the melting temperature of stem 
bromelain in the absence (~75-76 °C) and in presence (~84-86 °C) of E-64 was also 
maintained. However, aggregation was not maintained in the presence of EGCG as an 
increase in fluorescence intensity was observed in the presence of the stabilised complex 
(Figure 3.12). 
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Figure 3.12: The effect of compounds on a stabilized complex. The compounds Congo Red and 
EGCG were added to a typical protein-inhibitor complex. An amount of 17 µg protein, 18 µM Congo 
Red, 35 µM EGCG and 10X SYPRO orange dye were present in respective tubes. i). protein-inhibitor 
complex with Congo Red ii). Protein inhibitor-complex with EGCG, with panels a and b representing the 
fluorescence and the derivative curves respectively, the two vertical lines represent the Tm. The 
temperature range was set at 25-95 °C with temperature increment of 0.2 °C, holding time of 2 seconds 
and the gain held at 7 for each run. 
 
3.5.7. Peak recovery after the addition of more protein 
The principle of the DSF TSA is that after binding, the dye is released in solution which results 
in the decrease in the peak. The hypothesis of this experiment was that during protein 
aggregation by Congo Red, the dye does not bind and thus is still available in the solution. To 
investigate this hypothesis, stem bromelain was tested in the presence of Congo Red and run 
on the thermal shift assay. After the run, the same sample was cooled and to it 10 µg/ 
4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
T e m p e ra tu r e  C
F
lu
o
r
e
s
c
e
n
c
e
S te m  b ro m e la in  (S B ) S B  +  E -6 4 S B  +  C o m p o u n d S B  +  E -6 4  +  C o m p o u n d
4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
T e m p e ra tu r e  C
F
lu
o
r
e
s
c
e
n
c
e
L e ge nd
L e ge nd
L e ge nd
L e ge nd
4 0 6 0 8 0
-2
-1
0
1
2
3
T e m p e ra tu r e  C
d
F
/d
T
L e ge nd
L e ge nd
L e ge nd
L e ge nd
4 0 6 0 8 0
-2
-1
0
1
2
3
T e m p e ra tu r e  C
d
F
/d
T
L e ge nd
L e ge nd
L e ge nd
L e ge nd
i) 
ii) 
a b 
a b 
  
46 
 
25 µL of protein was added before undergoing a second run. This was done as the presence 
of 18 µM Congo Red aggregated the protein which completely removed the fluorescence peak 
(blue line Figure 3.13). The second run resulted in a recovered peak with a Tm of ~75-76 °C 
(red line Figure 3.13), which is identical to that of stem bromelain alone in the absence of 
Congo Red.  
 
 
 
 
 
 
 
     
     
4 0 6 0 8 0
0
5
1 0
1 5
2 0
2 5
D a ta  2 9
T e m p e ra tu re  C
F
lu
o
r
e
s
c
e
n
c
e
S te m  b ro m e la in  w ith  C o n g o  R e d  firs t ru n
s te m  b ro m e la in  w ith  C o n g o  R e d  re -ru n  w ith  a d d e d  p ro te in
                             
Figure 3.13: The recovery of a peak upon addition of protein. Stem bromelain was tested with 
Congo Red in the thermal shift assay, after the first run, 10 µg/ 25 µL of the protein was added and the 
assay was re-run in the absence of SYPRO orange dye. Results are presented in a fluorescence curve 
(Panel a) and derivative curve (panel b) and the black vertical line represents the Tm. The temperature 
range was set at 25-95 °C with temperature increment of 0.2 °C, holding time of 2 seconds and the gain 
held at 7 for both runs.  
 
3.5.8. Effect of detergent 
Detergent-based assays are extensively used to identify promiscuous compounds in drug 
discovery. As such, different concentrations of detergents were tested for their effect on the 
DSF assay to explore this knowledge. The presence of different concentrations of SDS 
increased the fluorescence intensity in the melt curve of stem bromelain (Figure 3.14). 
Additionally, a decrease in the Tm of stem bromelain was observed with increasing 
concentrations of SDS, this change was observed as a shift to the left (Figure 3.14). However, 
this shift was not observed in the presence of 0.004% SDS where the Tm of stem bromelain 
remained unaltered. A similar decrease in Tm was observed in previous reports (Yeh et al., 
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2006; Alexandrov et al., 2008). In contrast, Tween-20 and Triton-X100 displayed high 
background noise, as a result the curve could not be detected and thus prevented the 
determination of the melting temperature of the protein (results not shown). The effect of SDS 
on the thermal profile of stem bromelain in the presence of E-64, Congo Red and EGCG was 
compared in Figure 3.15. The Tm of the protein with E-64 remained ~84-86 °C in the presence 
and in the absence of the detergent. Interestingly, the thermal profile of stem bromelain in the 
presence of Congo Red was observed to be affected by SDS (Figure 3.15 iii). 
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Figure 3.14: The effect of SDS on bromelain in the presence of SYPRO orange dye. Stem 
bromelain at 17µg/ 25 µL was incubated with different concentrations of SDS for 30 minutes prior run 
in the thermal shift assay. The final dye concentration present in each tube was 10X. The fluorescence 
and derivative curves are represented in panels a and b respectively, the Tm is indicated by the black 
vertical line. The temperature range was set at 25-95 °C with temperature increment of 0.2 °C, holding 
time of 2 seconds and the gain held at 7. 
The peak previously aggregated by Congo Red in the absence of the detergent was recovered 
in the presence of the detergent. The recovered peak was observed at ~73-74 °C indicating a 
minimal shift to the left from the Tm of stem bromelain ~75-76 °C (Figure 3.15 iii). The thermal 
profile of stem bromelain in the presence of the compound EGCG was not altered by SDS 
(Figure 3.15 iv). Previous reports on detergent-based assays have indicated that aggregate-
based promiscuous compounds are affected by detergents whereas detergents have no effect 
on true inhibitors (Feng and Shoichet, 2006; Feng et al., 2007).
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Figure 3.15: The effect of SDS on compounds and inhibitor in the presence of SYPRO orange dye. Stem bromelain (SB) at 17 µg/ 25µL was tested with 
the compounds in the presence of 0.004% SDS in the thermal shift assay. i) stem bromelain with SDS ii). SB with 30 µM E-64 and SDS iii). SB with 18 µM 
Congo Red and SDS iv). SB with 25 µM EGCG and SDS. The dye was present in 10X final concentration in each tube. Panel a and b represent the fluorescence 
and derivative curves respectively. The temperature range was set at 25-95 °C with temperature increment of 0.2 °C, holding time of 2 seconds and the gain 
held at 7.
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3.6. Cytotoxicity assays  
The half maximal cytotoxicity concentration (CC50) of Congo Red and EGCG on HEK 293T 
cells were determined on the MTT assay and the results are shown as sigmoidal curves in 
Figure 3.16 and 3.17 respectively. Absorbances were taken at 590 nm wavelength and the 
CC50 was determined for each compound in the presence of different MTT solvents (Table 3 
and Table 4).  
Table 3.4: Data representing the levels of cytotoxicity of Congo Red in HEK 293T cells tested 
in the presence of different MTT solvents. 
Solvents  CC50 
SDS 20 ± 1.3 µM 
SDS/HCL 18 ± 1.25 µM 
SDS/HCL/Isopropanol 14 ± 1.13 µM 
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Figure 3.16: Cytotoxicity levels of Congo Red on HEK 293T cells using different solvents. The 
MTT assay was used to quantify cell viability in the presence of solvents where the absorbance was 
read at 590 nm wavelength. The experiment was done in triplicates and the averages are plotted as 
data points in the dose-response curves where the standard deviation is presented as error bars. Panels 
a (SDS), b (SDS/HCL) and C SDS/HCL/Isopropanol) represent different MTT solvents used for 
detection.
a b 
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Comparable cytotoxicity concentrations were observed for both Congo Red and EGCG in the 
presence of different MTT solvents. These results are in agreement with a study done in 2014 
where the CC50 of EGCG was reported to be 23 ± 1 µM (Abrahams, 2014). Weisburg and 
colleagues also reported a similar CC50 of 25 ± 4.2 µM on CAL27 cells (Weisburg et al., 2004). 
Conversely, Nance and colleagues reported that EGCG was not toxic to peripheral blood 
mononuclear cells at concentrations lower than 100 µM (Nance et al., 2009). 
 
Table 3.5: Data representing the levels of cytotoxicity of EGCG in HEK 293T cells tested in 
the presence of different MTT solvents. 
Solvents   CC50 
SDS  25 ± 1.41 µM 
SDS/HCL  19 ± 1.27 µM 
SDS/HCL/Isopropanol  24 ± 1.39 µM 
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Figure 3.17: Cytotoxicity levels of EGCG on HEK 293T cells using different solvents. The MTT 
assay was used to quantify cell viability in the presence of solvents where the absorbance was read at 
590 nm wavelength. The experiment was done in triplicates and the averages are plotted as data points 
in the dose- response curves where the standard deviation is presented as error bars. Panels a (SDS), 
b (SDS/HCL) and C SDS/HCL/Isopropanol) represent different MTT solvents used for detection.
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Chapter 4: Discussion 
Drugs that specifically target affected cells rather than interfering with the healthy cells present 
are sought in drug discovery. As such, specificity is a desirable trait in a drug. The drug 
discovery process is however, challenged with non-selective drug-like compounds that result 
in false positives. These compounds bind to unrelated targets in a non-specific manner and 
disturb or confuse the drug screening process. These compounds are called promiscuous 
inhibitors owing to their non-selective nature. In this study, we sought to develop a novel 
biochemical assay to identify promiscuous compounds. Briefly, the DSF thermal shift assay 
was adapted and optimized to study and compare the signatures of aggregate-based 
promiscuous inhibitors to those of true inhibitors. Fluorescence-based thermal shift assays are 
commonly used in drug discovery, however, this study presents a specific method to identify 
both true and promiscuous compounds. Specifically, this study compared true inhibitors of 
stem bromelain with known promiscuous compounds, however, this assay can potentially 
apply to other proteins or targets. Importantly, this is the first developed assay to concurrently 
identify both true and promiscuous inhibitors using a single assay. 
4.1. Stem bromelain is an ideal protein to use in the thermal shift assay 
Stem bromelain is the most active cysteine proteinase obtained from pineapple and it has 
various reported benefits (Maurer, 2001; Tochi et al., 2008; Pavan et al., 2012). Since this 
protein has not been previously used in the thermal shift assays, bioinformatics was seen a 
fitting start for this study. This was done to acquaint with the structure and the composition of 
the protein as both these factors are important for the thermal shift assay. Through 
bioinformatics, this study showed that stem bromelain is a hydrophobic protein. This was 
shown by the distribution of non-polar amino acid residues both in the core and surface of the 
protein (Figure 3.1). Even though it was not clear at this stage whether the hydrophobic 
surface of stem bromelain would interfere with the findings in the thermal shift assay, the 
hydrophobic core of this protein encouraged further investigations. The thermal shift assay 
uses environmentally sensitive fluorescent dyes such as SYPRO orange to track the unfolding 
transitions of the protein. The fluorescence of SYPRO orange is quenched in the aqueous 
environments, which validates the general downward trend from 25 - 65 °C observed in the 
melt curves in this study. However, an increase in temperature unfolds the protein, exposing 
its core hydrophobic regions. SYPRO orange exhibits an increased quantum yield at lower 
dielectric environment, such as the hydrophobic regions of the proteins. As such, the dye binds 
to the hydrophobic regions and becomes
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unquenched and this binding results to an increase in fluorescence. In the thermal shift assays 
conducted in this study, SYPRO orange was unquenched and was observed to bind to the 
non-polar residues of stem bromelain. This was indicated by an increase in fluorescence in 
the melt curve of stem bromelain at temperature 65-76 °C which further supported and 
correlated the hydrophobicity shown in bioinformatics.  
The detection of the protein’s Tm is the main objective of thermal shift assays. The temperature 
gradient created by the real-time PCR machine is generally from 25-95 °C, hence, ideal 
proteins to use in thermal shift assays should have melting temperatures that fall within this 
range. The theoretical Tm of stem bromelain is reported to be 77 °C at acidic pH (Haq et al., 
2005), hence, this validates the choice of using stem bromelain as a protein of interest as its 
Tm fall within the assay’s temperature range. These results were further validated in this study 
where stem bromelain yielded a Tm of ~75-76 °C. Furthermore, the Tm of stem bromelain is 
maintained in all tested concentrations, where even at low concentrations of 5 µM protein 
peaks were visible. This observation further confirmed stem bromelain to be a well-behaved 
enzyme suitable for the thermal shift assay.  
Even though commercially obtained as a pure enzyme, isolation through molecular exclusion 
chromatography and separation by SDS-PAGE revealed that stem bromelain still existed in a 
mixture of five proteins as per previous reports (El-Gharbawi and Whitaker, 1963). Following 
this observation, it was expected that in the thermal shift assay stem bromelain would produce 
five peaks due to the different proteins of different sizes obtained. This expectation was due 
to the thermal shift results obtained in a previous study were protein-protein interaction 
resulted in multiple peaks indicating the presence of different proteins (Layton and Hallinga, 
2011). However, in the present study a single peak was produced for the bromelain mixture. 
This could be due to a number of factors, one being the possibility that stem bromelain is in 
fact pure and the different proteins observed are a result of protein degradation. It could also 
be possible that the other present proteins are at low concentrations in the mixture and could 
not be detected in the thermal shift assay. The other proteins present in the mixture may 
possess melting temperatures that are either below 25 °C or above 95 °C, this would explain 
why they are not visible. Another possible explanation could be that all the proteins present in 
the bromelain mixture have a similar Tm of ~75-76 °C, hence the single peak. Stem bromelain 
was identified as the prominent band at 33.11 kDa (Figure 3.3) which was expected following 
previous reports (Ritonja et al., 1989; Margaretta et al., 2015). This size also correlated with 
the 33 kDa stem bromelain size predicted by ExPASy. The molecular weight of proteins used 
in thermal shift assays starts from 19 kDa (Ericsson et al., 2006). Stem bromelain at a size of 
33.11 kDa was therefore confirmed to be suitable for the thermal shift assay as it above this 
protein size. 
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In this study, stem bromelain was detected as an active enzyme following the successful 
degradation of the substrate gelatin in both the titrimetric and the radial diffusion assay. The 
activity of stem bromelain can be detected in the presence of other substrates such as casein. 
However, gelatin is favourable due to its availability and broad assay options. In the titrimetric 
assay, the enzyme yielded 2085.50 and 2024.36 GDU/ mg enzyme for 2 and 4-units enzyme 
respectively (Table 3.1).  A detection of the enzyme activity on the absorbance spectrum 
showed that stem bromelain is fully able to break down its substrate gelatin into oligopeptides 
and amino acids. This reaction stopped upon the addition of hydrogen peroxide (H2O2) (Figure 
3.4) and further titration with sodium hydroxide removed the amino acids (Dubey and Reddy, 
2012). Further substrate degradation by stem bromelain was correlated in the radial diffusion 
assay where degraded wells were not stained by Amido black. This confirmed that stem 
bromelain is structurally correct to use in the thermal shift assay (Figure 3.6). In summary stem 
bromelain was an ideal protein to use in the thermal shift assay as it is hydrophobic, structurally 
correct and well-behaved. Stem bromelain also has both the size and the melting temperature 
that falls within the range set for the thermal shift assay.  
 
4.2. E-64 stabilizes stem bromelain   
E-64 is an irreversible class specific cysteine protease inhibitor (Trinchese et al., 2008). In this 
study, the inhibition and stabilization of stem bromelain by E-64 was observed in the radial 
diffusion assay and in the thermal shift assay respectively. E-64 and another cysteine protease 
inhibitors, iodoacetate and TPCK, successfully inhibited the degradation of gelatin by stem 
bromelain in the radial diffusion assays. These inhibitors form bonds with the cysteine 
protease. Particularly, bonding with the thiol (-SH) regions of cysteine-containing proteins such 
as papain and bromelain results in full inhibition. This bond formation alters the structure of 
the enzymes thereby blocking the active sites which slows the activity of the enzyme. Mercury 
was also observed to inhibit stem bromelain and even though it is not a true inhibitor of 
cysteine protease, total inhibition of stem bromelain was expected following previous reports 
(Masdor, 2013).  
In the thermal shift assay, the binding of E-64 to the protein resulted in a more stable complex 
observed as a shift in the melting temperature of stem bromelain. As an irreversible inhibitor, 
E-64 interacts covalently with the protein and changes its conformation. This covalent 
attachment stabilizes the protein which then requires extreme temperatures to unfold, hence, 
the Tm increases to ~84- 86 °C. The shift observed is visible from interactions of low inhibitor 
concentrations (5 µM) with protein concentration of 17 µg/ 25 µL. 
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Interestingly, iodoacetate and TPCK did not cause a shift in the Tm of the protein. This 
indicated that there was no specific interaction between the inhibitors and the protein. Even 
though iodoacetate and TPCK are irreversible inhibitors like E-64, they are, however, not class 
specific to cysteine proteases as they inhibit different protease classes (Otto and Schirmeister, 
1997). This could be a possible explanation for the lack of effect observed in the thermal shift 
assay, nonetheless, shifts were expected in the presence of these inhibitors. In previous 
studies the presence of irreversible inhibitors demonstrated a shift in Tm and biphasic protein 
melt curves which was not the case in this study (Rojas et al., 2015; Bai et al., 2019). 
4.3. Aggregation of Stem bromelain by Congo Red was reversible in the 
presence of a detergent  
Promiscuous compounds generally interact with proteins in a non-specific manner, as a result, 
in their presence, the activity of the protein appears to be suppressed. Therefore, there is a 
drive to explore purpose specific assays that expose this non-specific inhibition. Congo Red 
is a known aggregate-based promiscuous compound that interacts with proteins of different 
or unrelated classes (Khurana et al., 2001). Like most promiscuous compounds, Congo Red 
forms micelle-like colloids and due to such factors, researchers are still not certain about the 
mechanism of interaction of this compound. In this study, the interaction of Congo Red with 
stem bromelain was investigated. Radial diffusion assays are typically used to determine 
enzyme activity where the activity is considered as the degradation of the substrate which is 
indicated by the cleared zone around the wells. Using this assay, Congo Red was observed 
to lack interaction with the protein as there was no interference with the protein’s activity. This 
was shown as cleared-zones on gelatin gel, however, at low concentrations of 8 µM Congo 
Red was observed to have a partially darker well than the other tested concentrations (Figure 
3.6). To confirm interference or lack of it, the activity of stem bromelain was investigated in the 
presence of other compounds that do not interfere with the activity of the protein. The 
compounds EDTA and soybean trypsin inhibitor are typical inhibitors of metallo and serine 
protease inhibitors respectively. Therefore, the lack of effect on stem bromelain as a cysteine 
protease was expected. However, there have been reports suggesting that soybean trypsin 
inhibitor deactivates through the cleavage of the C-terminal of arginine present in the protein 
(Ma, 2010; Sabotič et al., 2012; Chowdhury et al., 2014). The chelating agent EDTA has a 
great affinity for divalent cations such as Mg2+ and Ca2+ that are found ubiquitously in proteins. 
Nevertheless, the activation of stem bromelain by EDTA suggests the need for this chelator 
to bind to the cations for its activity. Overall, studying Congo Red in the radial diffusion assay 
was necessary as the partial inhibition observed guided studies in the thermal shift assay to 
further understand the effect of this aggregator on stem bromelain.
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In this study, low concentrations of 5 - 8 µM Congo Red did not alter stem bromelain’s Tm in 
the thermal shift assay. However, the presence of higher concentrations (9 - 18 µM) of the 
compound aggregated the protein which resulted in the low fluorescence intensity curve. The 
aggregation of the protein was observed to be concentration dependent, as higher 
concentrations of Congo Red completely sequestered the protein from the reaction. As a 
result, the melting temperature of stem bromelain could not be determined. These results 
supported reports that Congo Red is an aggregate-based promiscuous compound (McGovern 
et al., 2002; McGovern et al., 2003).  
Further investigations involved the use of the detergent since such surfactants have been 
promoted in assays to detect the presence of aggregate-based promiscuous compounds. The 
presence of the detergent SDS restored the protein which was indicated by an increase in the 
fluorescence curve previously aggregated by Congo Red. The presence of the detergent is 
known to degrade the colloid formed by aggregators, hence, the restored stem bromelain 
curve has a comparable Tm in the presence and in the absence of Congo Red. This provides 
further evidence that there is no direct interaction between the protein and Congo Red as 
predicted in the radial diffusion assay. Furthermore, these results confirmed that inhibition by 
aggregate-based promiscuous compounds is reversible upon the addition of a detergent. 
Toxicity is the main cause of late- stage failures in drug discovery where a number of approved 
drugs have been withdrawn from the market due to toxicities that were not detected in the late-
stages of clinical trials (Chen et al., 2013). As a result, cytotoxicity assays were conducted to 
assist in explaining this hypothesis. Promiscuous compounds are generally toxic and as 
expected, Congo Red had a toxicity of 20 ± 1.3 µM in HEK 293T cells in the cytotoxicity assays 
and yielded steep sigmoidal curves with steep hill slopes which further correlated the 
promiscuity of Congo Red.  
4.4. EGCG interacts with stem bromelain  
The compound (–)-epigallocatechin-3-gallate also known as EGCG belongs to the family of 
five catechins found in green tea where it is the most active. This polyphenolic natural 
compound is believed to have therapeutic benefits when consumed in green tea or taken in 
supplements (Nagle et al., 2006). Antioxidant effect, anti-cancer, a boost in cardiovascular 
health, skin protection from radiation are among the numerous benefits of EGCG (Nagle et 
al., 2006; Khan and Mukhtar, 2007; Forester and Lambert, 2011). Despite these benefits, not 
much is known about EGCG’s mechanism of action. Efforts to investigate this revealed that 
EGCG exhibits promiscuous binding and inhibits proteins of different origins (Liang et al., 
1997; Ehrnhoefer et al., 2008; Ishii et al., 2011). Here, EGCG was used to verify the objectives 
of this study.  
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In this study, radial diffusion assays detected no interaction between EGCG and stem 
bromelain. However, in the presence of 0.8 µM EGCG, the well is partially darker compared 
to the other concentrations. A similar observation was obtained with Congo Red at this 
concentration which indicated partial inhibition of stem bromelain. Furthermore, studies on the 
thermal shift assay correlated the partial interaction between the protein and EGCG. The 
presence of this compound increased the Tm of the protein in a manner comparable to that of 
E-64. This behaviour was expected as EGCG is a promiscuous compound and not an inhibitor 
of stem bromelain. Therefore, it was suspected that EGCG could not have specifically 
interacted with the protein in its active site. Previous reports supported this observation 
through suggestions that EGCG undergoes oxidation to form quinone that react with the 
nucleophilic thiol group of cysteine residues and as a result interact with the protein (Ishii et 
al., 2008). Furthermore, unlike with Congo Red, EGCG was not affected by the presence of 
the detergent. This showed that although EGCG non-specifically binds to stem bromelain, it 
was not through aggregation. Steep dose-response curves and toxicity at 25 ± 1.41 µM in 
HEK 293T cells in the cytotoxicity assays supported the hypothesis that EGCG is promiscuous 
as both these factors indicate promiscuity of the compound. 
 
4.5. The DSF thermal shift assay is a potential method for the identification of 
promiscuous compounds 
The DSF thermal shift assay is mostly known for monitoring protein to ligand binding in the 
presence of fluorescent dyes. Different fluorescent dyes are suitable for the thermal shift 
assays, however, SYPRO Orange has been successfully used and is favored due to its 
elevated signal to noise ratio (Lo et al., 2004). Here, the thermal stability of stem bromelain 
was studied in the presence of increasing concentrations of SYPRO orange dye, at different 
concentrations of protein and in the presence of increasing amounts of true and promiscuous 
inhibitors E-64, Congo Red and EGCG. An evaluation of the performance and robustness of 
Tm determination by DSF showed that the assay is effective with minimal dye and protein 
concentrations. This was evident during dye optimization assays as at 10X dye concentration, 
the protein had the highest fluorescence intensity. Furthermore, visible peaks were observed 
even with low concentrations of 5 µg protein, which is the minimum concentration tested in 
this study. Drug discovery is an expensive process that involves a series of tests to identify 
potential leads. During these tests, large amounts of resources are used. Therefore, having 
an assay that uses minimal resources is desirable. Furthermore, the success of the 
optimization of concentration-dependent assays showed that DSF assay can be used to 
screen a wide range of protein and compound concentrations. This is ideal for identifying
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promiscuous compounds as their interactions with proteins is concentration dependent, as 
confirmed in this study. A number of factors contribute to the stability of the protein which in 
thermal shift assays is shown by an elevated Tm. Examples of such factors include buffer 
contents such as salts and pH. The sodium acetate buffer containing sodium chloride has 
been used in stem bromelain assays and have previously shown to maintain the protein’s 
activity (Gautam et al., 2010). For thermal shift assays in this study, a buffer library was tested 
comparing buffers of different pH in the presence and the absence of a salt gradient. Stem 
bromelain was found to possess a higher Tm in the presence of the sodium acetate buffer 
containing sodium chloride at pH 4.5. Therefore, the ability to use the thermal shift assay to 
optimize conditions that maintain the stability of the protein makes this assay ideal, as target 
stability is a sought trait in drug discovery. 
4.5.1. The ability to detect partial unfolding, sequestering and restrain dynamics 
as mechanisms of action for promiscuous compounds 
Evidence that DSF thermal shift assay can be employed to distinguish between the 
mechanism of action for promiscuous compounds is provided. Two visible changes in the DSF 
curve were observed in the presence of Congo Red, one being an aggregated peak and the 
other being a shift to the left. These two observations were suspected to present the methods 
of interaction between Congo Red and stem bromelain. The three possible mechanisms 
suspected to have occurred in this study; partial unfolding, sequestering and restrained 
dynamics are discussed below.  
The shift to the left was suspected to be due to partial protein unfolding, which is one of the 
reported mechanisms of action for the aggregate-based promiscuous compounds (Coan et 
al., 2009). Even though we are fully aware that several other factors could have contributed to 
the decrease in the Tm, the fact that it occurred in the presence of Congo Red encouraged the 
partial unfolding suspicions. According to Coan and colleagues, upon interaction with proteins, 
aggregate-based promiscuous compounds unfold the protein’s structure resulting in 
decreased or no activity (Coan et al., 2009). Furthermore, this decrease in Tm was maintained 
in the recovered peak of stem bromelain in the presence of Congo Red and SDS. Therefore, 
these results support partial unfolding as the mechanism of interaction between promiscuous 
compounds and proteins.  
The concentration-dependent protein aggregation by Congo Red could possibly present two 
other mechanisms of action previously determined for aggregate-based promiscuous 
compounds. The first proposed mechanism is restrained dynamics, here, Congo Red could
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have restrained movement of the protein making it rigid. This could have prevented the protein 
from unfolding at ~75-76 °C as this is where it was expected to melt. This consequently, 
prevented the dye from binding and hence no increase in fluorescence which accounts for the 
lack of the Tm determination. The second mechanism of action evident here can be 
sequestering, where Congo Red could have formed colloids which aggregated and completely 
sequestered the protein from the reaction. Once sequestered, the protein, as in the restrained 
dynamics model, could not be accessed and as a result the melting temperature could not be 
determined.   
The investigations of the protein-inhibitor complex in the presence of promiscuous compounds 
were guided by the efforts to further validate these proposed mechanisms. It was evident in 
these assays that aggregation in the presence of Congo Red was not specifically for proteins, 
but aggregation can occur in the presence of a stabilized complex (protein-inhibitor complex) 
(Figure 3.12). This result was shown as a decreased protein fluorescent peak in the presence 
and in the absence of the inhibitor (Figure 3.12). It is also evident in Figure 3.12 that although 
aggregated, Congo Red did not directly interact with the protein-inhibitor complex as the shift 
is still observed. Furthermore, this showed that partial unfolding in the presence of an 
aggregate based compound is selective to proteins. This observation was justified by the 
maintained Tm of the protein-inhibitor complex (~84-86 °C) whereas in the presence of the 
protein alone, the partial shift was still visible.  
The DSF thermal shift assay is influenced by the binding of the SYPRO orange dye, with the 
principle that the increase in fluorescence intensity is due to the dye binding to unfolded 
proteins. However, If the protein remains folded the SYPRO orange remains unbound in 
solution. This was considered the case with aggregation of stem bromelain by Congo Red, as 
increase in fluorescence was not observed which meant the dye was still accessible. This 
principle was supported by the recovery of an already aggregated protein-Congo Red peak 
upon the addition of more protein (Figure 3.13). Additionally, these results supported the 
principle as the dye was still available in solution to bind to the protein resulting in a partially 
decreased Tm of 72-73 °C. Furthermore, this observation also supported the reports that 
increasing protein concentration can gradually reverse or decrease inhibition by promiscuous 
compounds (McGovern et al., 2002). Overall, these results correlated the three proposed 
mechanisms; unfolding shown as decrease in Tm in the recovered peak; restrained dynamics 
and sequestering which resulted in a flattened protein peak. It was finally concluded that 
restrained dynamics, sequestering and unfolding could possibly occur concurrently. 
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4.5.2. The ability to use detergents for the detection of aggregate-based 
promiscuous compounds  
Detergents are a widely used tool in drug discovery and have since been rescuing screening 
assays as they are able to expose the presence of aggregate-based promiscuous compounds. 
This owes to the detergents’ ability to decrease the surface tension of these compounds. 
However, detergents are among the components that have been predicted to cause potential 
destabilization and unfolding of proteins in thermal shift assays (Yeh et al., 2006; Alexandrov 
et al., 2008). Here, this study supported this finding as in the presence of high SDS 
concentrations the Tm of the protein was altered. Surprisingly, in the presence of low 
concentration (0.004%) of SDS the Tm of stem bromelain was maintained. Therefore, this 
study provides evidence which suggest that this detergent can be applied in thermal shift 
assays under these specified conditions. Normally, detergent-based assays use non-ionic 
detergents such as Triton-X100 and Tween 20. However, these latter detergents adversely 
affected the ability to monitor fluorescence changes of the protein in this study. 
The detergent SDS remarkably restored the protein peak previously aggregated by Congo 
Red, while no change was observed in the presence and the absence of E-64 and EGCG. As 
proof of concept, this study showed that the DSF thermal shift assay can be used to 
successfully distinguish between aggregate- based promiscuous inhibitors (Congo Red) and 
true inhibitor (E-64) in the presence of SDS. 
4.6. Conclusion  
Commercial stem bromelain was isolated through molecular exclusion chromatography and 
the protein separation was achieved by SDS-PAGE with the prominent band at 33.11 kDa as 
indicated by previous studies. The enzyme was confirmed structurally correct in the gelatin 
titrimetric enzyme activity assay with the activity measured in GDUs. Promiscuous compounds 
Congo Red and EGCG were investigated in the radial diffusion assays and were predicted to 
not interfere with the activity of stem bromelain when compared with known activators and 
inhibitors of the enzyme. DSF thermal shift assays were optimized to compare the effects of 
E-64 the true-inhibitor of stem bromelain with that of Congo Red and EGCG where the 
mechanism of action for each compound was predicted. Aggregation of stem bromelain by 
Congo Red was predicted to occur through three mechanisms; sequestering, restricted 
dynamics and unfolding which were observed to occur concurrently. Additionally, EGCG was 
predicted to accomplish non-specific binding, however, it does not achieve it through 
aggregation. The use of the detergent SDS (at a specific concentration) in the DSF thermal 
shift assay confirmed that Congo Red was an aggregator, while EGCG and E-64 were not
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affected by the presence of SDS. Both Congo Red and EGCG demonstrated cytotoxicity. 
Overall, this study successfully demonstrated that the DSF thermal shift assay can be used to 
concurrently distinguish between a true and promiscuous compound, moreover, this assay 
can be used to determine the mechanism of action of compounds. 
 
4.7. Future works 
The results obtained in this study can be advanced in the following ways;  
1. Evaluation of a compound library to identify aggregate-based compounds and 
compare different mechanism on the thermal shift assay. A compound library 
consisting of both natural compounds and commercial compounds can be screened in 
the thermal shift assay under the conditions optimized in this study to identify or 
compare the behaviour of the different compounds. 
2. Comparing the effect of other aggregators such as Rottlerin and methylene blue on 
different proteins and their ligands using the DSF thermal shift assay. The promiscuous 
compounds can be tested for their effect on proteins of unrelated origins, of different 
functions and sizes. This will correlate the promiscuity of these compounds.  
3. Screening of different inhibitors for different targets to identify which are true inhibitors.  
4. Optimizing the detergent-based thermal shift assays with different detergents such as 
CHAPS and chloric acid to see if their presence can restore the fluorescent peak of 
the protein without affecting the melting temperature.  
5. Validating the interaction of promiscuous compounds with other more sensitive thermal 
shift assays such as CETSA, DSLS, and DSC. 
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